: The AMEDEO Literature Guide

Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Gynecology

Free Subscription

Articles published in Gynecol Oncol
Retrieve available abstracts of 770 articles:
HTML format

Single Articles

September 2026

RAFFONE A, Neola D, Tranchini A, Mele M, et al
Molecular groups predict response to fertility-sparing treatment of endometrial carcinoma: a systematic review and metanalysis.
Gynecol Oncol. 2026;213:25-32.
PubMed Abstract available

SILK T, Matulonis UA, Konstantinopoulos PA
Molecular characterization of NSMP endometrial cancer and its relevance for treatment.
Gynecol Oncol. 2026;213:15-24.
PubMed Abstract available

August 2026

THAYER EG, Roecker ZA, Roof KA, Gold HB, et al
High rates of venous thromboembolism in endometrial cancer patients requiring systemic therapy: an opportunity for risk assessment and intervention.
Gynecol Oncol. 2026;213:1-6.
PubMed Abstract available

CHAPMAN GC, Fedorenko O, Sheyn D, Reid A, et al
Leveraging artificial intelligence in the early detection of ovarian cancer: Development and validation of a risk prediction model.
Gynecol Oncol. 2026;212:199-206.
PubMed Abstract available

AGUSTI N, Bercow A, Knisely A, Obermair A, et al
The science and conduct of surgical trials in gynecologic oncology: A practical framework.
Gynecol Oncol. 2026;212:188-198.
PubMed Abstract available

RICHARDSON MT, Barry D, Steinberg JR, Holder K, et al
Early-phase vs. late-phase clinical trials in gynecologic oncology: Trends in trial completion, reporting, and enrollment of racial and ethnic minority groups.
Gynecol Oncol. 2026;212:181-187.
PubMed Abstract available

WESTIN SN, Belotte J, Felicetti B, Aghera V, et al
Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial.
Gynecol Oncol. 2026;212:173-180.
PubMed Abstract available

KO EM, Pae C, Mulugeta-Gordon L, Uwawaike D, et al
Evaluating a patient ambassador program to improve clinical trial knowledge and intent to discuss gynecologic oncology trials.
Gynecol Oncol. 2026;212:160-172.
PubMed Abstract available

RIESE C, Yi-Tung E, Nilsson H, Salehi S, et al
Incidence, prevalence, mortality and survival trends in women with endometrial-, ovarian- and cervical cancer in the Nordic countries (1980-2023) with focus on younger women (0-49 years old).
Gynecol Oncol. 2026;212:152-159.
PubMed Abstract available

AINIO C, Caruso G, Alessi S, Aiello AA, et al
Predicting residual disease and extent of surgery after neoadjuvant chemotherapy for ovarian cancer: Does the MSKCC model from the primary setting apply?
Gynecol Oncol. 2026;212:145-151.
PubMed Abstract available

NGUYEN AQ, Bednarek N, Al-Sawalha I, Nagele B, et al
Feedback activation of MAPK-ERK1/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers.
Gynecol Oncol. 2026;212:134-144.
PubMed Abstract available

HARRINGTON S, El Ghazal N, Tung C, Husain F, et al
The role of metabolic and bariatric surgery for obesity management in endometrial intraepithelial neoplasia and endometrial cancer: A Society of Gynecologic Oncology and Society of American Gastrointestinal and Endoscopic Surgeons clinical practice st
Gynecol Oncol. 2026;212:31-42.
PubMed Abstract available

SEO JH, Lee Y, Lim S, Chung YE, et al
Dynamics of HER2 status in recurrent cervical cancer: Highlighting the clinical value of reassessment.
Gynecol Oncol. 2026;212:125-133.
PubMed Abstract available

ALEVATO R, Braga A, Paiva G, Junior EA, et al
Persistent low-level real human chorionic gonadotropin after gestational trophoblastic disease: Natural history and predictors of subsequent gestational trophoblastic neoplasia.
Gynecol Oncol. 2026;212:116-124.
PubMed Abstract available

HOPP EE, Enserro D, Campos S, Chitiyo V, et al
A phase II study of androgen receptor inhibition by darolutamide in combination with leuprolide acetate and exemestane in recurrent adult-type ovarian granulosa cell tumor.
Gynecol Oncol. 2026;212:98-105.
PubMed Abstract available

KOCIAN R, Koehler C, Di Martino G, Klat J, et al
Quality of life outcomes after sentinel lymph node biopsy in patients with early-stage cervical cancer: Results from the prospective multicentre SENTIX study.
Gynecol Oncol. 2026;212:106-115.
PubMed Abstract available

OXLEY S, Dibden A, Whenham T, Wei X, et al
Health-related quality of life after risk-reducing hysterectomy: a randomised vignette study.
Gynecol Oncol. 2026;212:89-97.
PubMed Abstract available

LANGE P, Kanal SA, Vidwans Y, Donneyong M, et al
Factors associated with non-completion of gynecological cancer clinical trials.
Gynecol Oncol. 2026;212:80-88.
PubMed Abstract available

DE TOMMASI O, Palmieri L, Bellone S, Buza N, et al
Integrated expression profiling of trophoblast cell-surface antigen 2 (TROP2), folate receptor alpha (FRalpha), and human epidermal growth factor receptor 2 (HER2) in endometrial Cancer across molecular classes, genomic alterations, and histologic sub
Gynecol Oncol. 2026;212:72-79.
PubMed Abstract available

WANG CC, Kildee I, Reasner E, Bednorski I, et al
Feasibility, adherence, and patient experiences in a pilot randomized trial of home-based cognitive training intervention for gynecologic cancer-related cognitive impairment.
Gynecol Oncol. 2026;212:64-71.
PubMed Abstract available

HELPMAN L, Josephy D, Toderis L, Tkach V, et al
Oral anticoagulants reduce venous thromboembolism rates in patients on 1st-line treatment for ovarian Cancer- A quality improvement project.
Gynecol Oncol. 2026;212:57-63.
PubMed Abstract available

AUBREY C, Svajger B, Batara J, Chapelsky S, et al
The feasibility of a medically supervised preoperative weight loss program in patients with obesity and atypical hyperplasia, or low-grade endometrial carcinoma.
Gynecol Oncol. 2026;212:50-56.
PubMed Abstract available

CHESS I, Holtzman S, Cox M, Leschly J, et al
"I was in the driver's seat": A qualitative analysis of factors promoting and delaying previvors' oophorectomy after risk-reducing salpingectomy.
Gynecol Oncol. 2026;211:200-207.
PubMed Abstract available

MARADIYA R, Kinloch M, De Leo A, de Biase D, et al
The real-world utility of homologous repair deficiency testing in BRCA1/2 wild-type high-grade serous carcinoma and the utility of MYC amplification as a potential surrogate marker.
Gynecol Oncol. 2026;211:148-152.
PubMed Abstract available

JIANG A, Chen Y, Ma F, Zhang H, et al
Malignant transformation risk and management dilemmas of atypical lobular endocervical glandular hyperplasia: A retrospective cohort study comparing Peutz-Jeghers syndrome versus sporadic cases.
Gynecol Oncol. 2026;211:51-58.
PubMed Abstract available

MAIORANO MFP, Cormio G, De Serio I, Torzillo FP, et al
Occult invasive and preneoplastic lesions at risk-reducing salpingo-oophorectomy in BRCA1/2 carriers: A multicenter retrospective cohort study.
Gynecol Oncol. 2026;211:29-36.
PubMed Abstract available

MCALPINE JN, Mutch D
A path to precision in endometrial cancer management: Moving past FIGO 2023.
Gynecol Oncol. 2026;211:A1-A2.
PubMed

July 2026

GOON KC, Chor J, Mills KA
Pregnancies in gynecologic oncologists: An assessment of pregnancy policies and complications within a surgical subspecialty.
Gynecol Oncol. 2026;212:24-30.
PubMed Abstract available

BOITANO TKL, Bansal A, Dinkins KG, Fennell V, et al
Understanding and addressing enrollment gaps and opportunities in gynecologic oncology clinical trials: A scoping review.
Gynecol Oncol. 2026;212:9-16.
PubMed Abstract available

FARABEE EA, Ahrendt HD, Lin M, Uczkowski NG, et al
Failure to rescue after major gynecologic cancer surgery: A National Surgical Quality Improvement Program analysis.
Gynecol Oncol. 2026;211:246-253.
PubMed Abstract available

NOGUERAS GONZALEZ GM, Amboree TL, Parker S, Bulsara S, et al
Barriers to cervical cancer screening and experiences using mailed at-home HPV self-collection kits among US and foreign-born Hispanic women in a safety net health system.
Gynecol Oncol. 2026;211:238-245.
PubMed Abstract available

BORDEN LE, Cosgrove CM, Washington CR, Thomas SM, et al
MLH1 promoter hypermethylation and associations with survival outcomes: A real-world endometrial cancer molecularly targeted therapy consortium cohort study.
Gynecol Oncol. 2026;211:231-237.
PubMed Abstract available

DUKES D, Yost C, Wang R, Diagne YF, et al
Guideline-anchored retrieval-augmented generation outperforms baseline and literature-only configurations in gynecologic oncology decision support: A pre-integration benchmark.
Gynecol Oncol. 2026;211:224-230.
PubMed Abstract available

CATOZZO A, Garzon S, Renso M, Raspagliesi F, et al
Clinical utility of sentinel lymph node biopsy in atypical endometrial hyperplasia: A multicenter cohort study.
Gynecol Oncol. 2026;211:217-223.
PubMed Abstract available

LEITE LF, da Conceicao LD, de Almeida LFC, de Albuquerque LZ, et al
Ovarian cancer global trends and disparities across 204 countries and territories.
Gynecol Oncol. 2026;211:208-216.
PubMed Abstract available

OTTUM S, Sethi N, Bellone S, Demirkiran C, et al
Preclinical activity of tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, in uterine serous carcinoma.
Gynecol Oncol. 2026;211:191-199.
PubMed Abstract available

O'CONNOR RM, Chalif J, Gonzalez A, Glassman DC, et al
Outcomes following complete response to immune checkpoint inhibitors in endometrial cancer.
Gynecol Oncol. 2026;211:185-190.
PubMed Abstract available

SEGUIN CL, Eckel A, Howard DH, Peters MLB, et al
Cost-effectiveness of a bevacizumab biosimilar for the treatment of recurrent, platinum-sensitive ovarian cancer in the United States.
Gynecol Oncol. 2026;211:178-184.
PubMed Abstract available

BARBER EL, Wei JJ, Strickland AL, Moroney JW, et al
Surgical window of opportunity clinical trial of abemaciclib and letrozole for endometrioid adenocarcinoma of the endometrium.
Gynecol Oncol. 2026;211:171-177.
PubMed Abstract available

ZHAO CL, Wang XP, Wei K, Ge YJ, et al
Folate receptor alpha, TROP2 and HER2 in high-grade serous ovarian Cancer: Expression and clinicopathological correlations.
Gynecol Oncol. 2026;211:162-170.
PubMed Abstract available

JEONG S, Kim S, Ouh YT, Lee S, et al
Validation of the 2025 ESGO/ESTRO/ESP postoperative risk stratification system in endometrial cancer: A same-cohort comparison with the 2020 molecular classification.
Gynecol Oncol. 2026;211:153-161.
PubMed Abstract available

ZIMMERMAN J, Dadgar N, Krivak TC, Crafton SM, et al
Immune checkpoint inhibition in ovarian cancer: Reassessing its potential.
Gynecol Oncol. 2026;211:138-141.
PubMed

DILLON BS, Hood O, Chanda S, Madill M, et al
An analysis of the readability of Gynecologic Cancer patient education materials.
Gynecol Oncol. 2026;211:142-147.
PubMed Abstract available

HAIGHT PJ, Sakach JC, Chambers LM, Backes FJ, et al
Response to mirvetuximab soravtansine and weekly paclitaxel based on treatment sequencing in platinum-resistant ovarian cancer: Does order matter?
Gynecol Oncol. 2026;211:132-137.
PubMed Abstract available

RICH BS, Fishbein JS, Purcell LN, Murphy JT, et al
Immature teratoma of the ovary with microscopic yolk sac tumor in children and adolescents: A multi-institutional study.
Gynecol Oncol. 2026;211:125-131.
PubMed Abstract available

RICH BS, Fishbein JS, Purcell LN, Murphy JT, et al
Immature teratoma of the ovary in children and adolescents: A multi-institutional study of characteristics and management.
Gynecol Oncol. 2026;211:115-124.
PubMed Abstract available

CATENA U, Dinoi G, Masciullo V, D'Alessandris N, et al
Fertility-sparing treatment in stage IA grade 2 endometrioid endometrial cancer: Outcomes of a standardized approach.
Gynecol Oncol. 2026;211:108-114.
PubMed Abstract available

ROLLER L, Zhou N, Atre I, Xiong N, et al
Toward precision prognosis: Predicting recurrence-free survival in high-grade serous ovarian cancer patients using multi-time point clinical and computed tomography radiomics data.
Gynecol Oncol. 2026;211:98-107.
PubMed Abstract available

YEN TT, Lu CA, Hsieh TYJ, Lee GY, et al
Adjunctive sodium-glucose cotransporter 2 (SGLT2) inhibitors with progestins and endometrial cancer risk in benign uterine diseases and hyperplasia.
Gynecol Oncol. 2026;211:89-97.
PubMed Abstract available

SHAHIN MS, Lorusso D, Backes FJ, Barretina-Ginesta MP, et al
Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.
Gynecol Oncol. 2026;211:79-88.
PubMed Abstract available

HAZNEDAR T, Durante S, Lazzari R, Corrao G, et al
Stereotactic body radiotherapy for oligorecurrent granulosa cell tumours.
Gynecol Oncol. 2026;210:140-147.
PubMed Abstract available

ABDEEN CS, O'Connor RM, Chalif J, Glassman DC, et al
Beyond extrapolation: Immunotherapy outcomes in recurrent vulvovaginal carcinoma.
Gynecol Oncol. 2026;210:72-76.
PubMed Abstract available

LANGSTRAAT CL, Ostby SA, Vu A, Kalogera ES, et al
Innovation through standardization: Reducing the ileostomy rates while targeting zero anastomotic leaks at cytoreductive surgery.
Gynecol Oncol. 2026;210:49-54.
PubMed Abstract available

LLOYD-ELLIS S, Kaur P, Kwon JS, Dawson L, et al
Uptake of risk-reducing medical interventions among female BRCA1/2 pathogenic variant carriers: A population-based study in British Columbia.
Gynecol Oncol. 2026;210:41-48.
PubMed Abstract available

SMITS A, Dhanis J, Drager LD, de Hullu J, et al
The impact of multimodal prehabilitation on surgical outcomes in gynaecological cancer surgery.
Gynecol Oncol. 2026;210:32-40.
PubMed Abstract available

TROZZI R, Anderson G, Romano V, Iacobelli V, et al
A review of reviews of the prevalence of molecular biomarkers in vulvar cancer and their implications for prognosis refinement and treatment strategies.
Gynecol Oncol. 2026;210:20-31.
PubMed Abstract available

URMAN RD, Ljungqvist O
The evolving landscape of personalized perioperative care: A commentary on the 2026 ERAS(R) Gynecologic oncology guidelines.
Gynecol Oncol. 2026;210:A1-A2.
PubMed

June 2026

CHAMBERS LM, Spakowicz D, Chalif J, O'Connor R, et al
PRO-PLATINUM: A randomized, double-blind, placebo controlled study to investigate the efficacy of a probiotic intervention on the gut and vaginal microbiome of ovarian cancer patients undergoing treatment with platinum chemotherapy.
Gynecol Oncol. 2026;211:74-78.
PubMed Abstract available

MONTASSIER T, Laas E, Hotton J, Berton-Rigaud D, et al
Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network.
Gynecol Oncol. 2026;211:59-66.
PubMed Abstract available

KOURI A, Menzies A, Stearns K, McGough C, et al
A second chance for the second look: Feasibility of laparoscopic HIPEC at the conclusion of upfront treatment for epithelial ovarian cancer.
Gynecol Oncol. 2026;211:67-73.
PubMed Abstract available

YARUNIN A, Qiu P, Li X, Lukashchuk N, et al
Technical evaluation of commercially available homologous recombination deficiency assays using MyChoice CDx as reference in ovarian cancer.
Gynecol Oncol. 2026;210:217-225.
PubMed Abstract available

ROY A, Iacob S, Chaffin A, Cunningham M, et al
FIGO 2023 staging may result in overtreatment of early-stage endometrial cancer.
Gynecol Oncol. 2026;211:46-50.
PubMed Abstract available

FENG P, Shi K, Zhao W, Zhang J, et al
Diagnostic value of FAM19A4/SOX1/PAX1 methylation in non-16/18 high-risk HPV cervical lesions.
Gynecol Oncol. 2026;211:37-45.
PubMed Abstract available

SULEIMAN R, Mokshagundam S, Block MS, Wahner Hendrickson AE, et al
Prehabilitation during neoadjuvant chemotherapy in advanced ovarian cancer is associated with improved surgical candidacy and chemotherapy outcomes.
Gynecol Oncol. 2026;211:9-16.
PubMed Abstract available

BERGERON AM, Kisiel M, Lavecchia M, Mah S, et al
Could chemotherapy response score act as a surrogate marker of response to PARP inhibitor maintenance treatment in patients with advanced ovarian cancer?
Gynecol Oncol. 2026;211:23-28.
PubMed Abstract available

LEE J, Seo K, Kim J, Son JH, et al
Corrigendum to "Evaluating alternative protocols for preventing cisplatin-induced acute kidney injury during hyperthermic intraperitoneal chemotherapy in ovarian cancer" [Volume 208, May 2026, Pages 85-90].
Gynecol Oncol. 2026;211:8.
PubMed

ALASHQAR A, Clark M, Gross CP, Spatz ES, et al
Cardiovascular outcomes in individuals with ovarian cancer: A retrospective cohort study.
Gynecol Oncol. 2026;211:17-22.
PubMed Abstract available

MAH SJ, Bergeron AM, Hanley G, Yang I, et al
Opportunistic salpingectomy during non-gynecologic surgery: Canadian surgeons' experience, barriers and facilitators.
Gynecol Oncol. 2026;211:1-7.
PubMed Abstract available

GAILLARD S, Parker J, Broadwater G, Duska L, et al
Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study.
Gynecol Oncol. 2026;210:208-216.
PubMed Abstract available

DESRAVINES N, Tschudy MM, Hazimeh D, Brown K, et al
Raising the bar on surgical site infection bundles: Preoperative penicillin allergy testing in gynecologic oncology patients with a reported penicillin allergy - A quality improvement study.
Gynecol Oncol. 2026;210:200-207.
PubMed Abstract available

LLANORA JD, Hayse C, Janke MJ, Liu Y, et al
Referral patterns for genetic counseling and completion of germline testing in patients younger than 50 years with endometrial cancer.
Gynecol Oncol. 2026;210:193-199.
PubMed Abstract available

VALSTAD H, Fauske L, Wang YY, Eyjolfsdottir B, et al
Pelvic exenteration for cervical cancer - Oncologic outcome and long-term health-related quality of life, a mixed methods study.
Gynecol Oncol. 2026;210:183-192.
PubMed Abstract available

TANG X, Huang H, Peipert JD, Zola A, et al
Psychometric evaluation of the NFOSI-18 disease related symptoms - Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004.
Gynecol Oncol. 2026;210:174-182.
PubMed Abstract available

NELSON G, Altman AD, Metcalfe A, Fotopoulou C, et al
Enhanced recovery after surgery (ERAS(R)) society guidelines for gynecologic oncology: 2026 update.
Gynecol Oncol. 2026;210:153-173.
PubMed Abstract available

KONG TW, Lee J, Kim J, Son JH, et al
A multicenter study of laparoscopic versus laparotomic surgery in the treatment of stage I adult granulosa cell and Sertoli-Leydig cell tumors: (LARGES): Gynecologic Oncology Research Investigators coLLaborAtion study (GORILLA-3005).
Gynecol Oncol. 2026;210:148-152.
PubMed Abstract available

CARVALHO SN, Soldin I, Silva RM, Domingues TD, et al
Clinical relevance of homologous recombination repair gene alterations in endometrial cancer patients in the era of molecular classification.
Gynecol Oncol. 2026;210:124-130.
PubMed Abstract available

LEE YJ, Park J, Kim YN, Kim S, et al
Histology-specific ADC target landscapes in ovarian cancer and therapy-associated antigen downshift after ADC exposure.
Gynecol Oncol. 2026;210:131-139.
PubMed Abstract available

GONZALEZ-BOSQUET J, Shahi M, Yadav S, Kanwar N, et al
Clinical relevance of transcriptome profiling for assessing prognosis, platinum insensitivity, and precision therapeutics in endometrial cancer.
Gynecol Oncol. 2026;210:114-123.
PubMed Abstract available

BOGANI G, Moore KN, Ray-Coquard I, Ceccaroni M, et al
Corrigendum to 'Endometriosis and ovarian cancer risk' [Gynecologic Oncology 209C (2026) 88-98].
Gynecol Oncol. 2026;210:113.
PubMed

PANDRAKLAKIS A, Shearer AM, Ellis LB, Oikonomou MD, et al
Primary ovarian malignant melanoma: A systematic review of cases and pooled analysis.
Gynecol Oncol. 2026;210:95-105.
PubMed Abstract available

WOLSWINKEL JT, Bekkers AHPA, Maurits JSF, Bekkers RLM, et al
Preoperative LVSI assessment in early-stage cervical cancer: Can it reliably guide lymph node management?
Gynecol Oncol. 2026;210:106-112.
PubMed Abstract available

KARLSEN NS, Hogdall CK, Dreisler E, Sakse AE, et al
Adding HE4 to the IOTA ADNEX model for differentiating adnexal masses: A Danish prospective, multicenter study.
Gynecol Oncol. 2026;209:111-119.
PubMed Abstract available

ZHANG X, Shahryari J, Kingsley LG, McCluggage WG, et al
Expression of the antibody-drug conjugate targets TROP2, CLDN6, B7-H3, and DLL3 in mesonephric-like adenocarcinoma of the female genital tract.
Gynecol Oncol. 2026;209:62-68.
PubMed Abstract available

SALANI R, Chase DM, Karlan BY
En-Do's and En-Don'ts: Navigating the rapidly evolving clinical landscape in endometrial cancer.
Gynecol Oncol. 2026;209:A1-A2.
PubMed

May 2026

SOIFFER JL, Suresh D, Jalai C, Xu Y, et al
Risk of endometrial carcinoma in patients with atypical endometrial hyperplasia in a population of predominantly racial and ethnic minorities, a single institution study.
Gynecol Oncol. 2026;210:77-83.
PubMed Abstract available

DIXIT R, Chakrawal A, Purwar R, Pandey M, et al
Comparative performance of HPV self-sampling and conventional screening methods: A systematic review and bivariate meta-analysis.
Gynecol Oncol. 2026;210:84-94.
PubMed Abstract available

POWELL MA, Roed H, Willmott LJ, Cibula D, et al
Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.
Gynecol Oncol. 2026 May 29:S0090-8258(26)01985.
PubMed Abstract available

KUROKI LM, Enserro DM, Lankes HA, Strickland KC, et al
Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249.
Gynecol Oncol. 2026;210:63-71.
PubMed Abstract available

SMICK AH, Zurek N, Taylor-Harding B, Karlan BY, et al
Molecular and spatial differences in the tumor microenvironment of high-grade serous ovarian cancers with short versus long-term survival.
Gynecol Oncol. 2026;210:55-62.
PubMed Abstract available

BORCINOVA M, Knize M, Brtnicky T, Presl J, et al
Multimodal prehabilitation in patients with advanced ovarian cancer.
Gynecol Oncol. 2026;210:10-19.
PubMed Abstract available

BRAND-WIITA S, Tsai CJ, Liu YH, Beaulieu E, et al
Cost-effectiveness of pembrolizumab as a treatment for FIGO 2014 stage III-IVA cervical cancer in the United States.
Gynecol Oncol. 2026;210:1-9.
PubMed Abstract available

SARGAZI N, Afshari S, Nahvijou A, Daroudi R, et al
Cost-effectiveness of Pembrolizumab in advanced endometrial cancer: A systematic review.
Gynecol Oncol. 2026;209:146-157.
PubMed Abstract available

JAMIESON A, Kwon J, Gao T, Lee J, et al
Assessing the essential parameters of race, ethnicity and geography in endometrial cancer and the impact on presentation, treatment and outcomes.
Gynecol Oncol. 2026;209:158-166.
PubMed Abstract available

FINCH L, Dagher C, Harlev C, Finlan M, et al
Preoperative hypoalbuminemia and survival among patients selected for primary cytoreduction in advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol. 2026;209:138-145.
PubMed Abstract available

CAO Y, Liu Q, Zhou H, Yu M, et al
Longitudinal trajectories of anxiety and depression in patients with endometrial cancer or atypical endometrial hyperplasia undergoing fertility-sparing treatment.
Gynecol Oncol. 2026;209:131-137.
PubMed Abstract available

URBAN R, Eskander R, Westin S, Powell M, et al
Endometrial cancer: A Society of Gynecologic Oncology evidence-based review and recommendations, part II.
Gynecol Oncol. 2026;209:120-130.
PubMed Abstract available

TURNER KA, Edwards CC, Ketch PW, Dinkins KG, et al
A phase Ib/II single-arm study of cabozantinib plus dostarlimab in women with recurrent gynecologic carcinosarcoma.
Gynecol Oncol. 2026;209:107-110.
PubMed Abstract available

PHUNG MT, Barroilhet LM, Binkley N, Gangnon RE, et al
Longitudinal dynamics of post-diagnosis frailty among older women with ovarian cancer.
Gynecol Oncol. 2026;209:99-106.
PubMed Abstract available

BOGANI G, Moore KN, Ray-Coquard I, Ceccaroni M, et al
Endometriosis and ovarian cancer risk.
Gynecol Oncol. 2026;209:88-98.
PubMed Abstract available

SHACHAR E, Rotkop G, Haas R, Frankenthal R, et al
Real-world genetic testing data of ovarian cancer patients: Informing counseling and risk reduction in patients over age seventy.
Gynecol Oncol. 2026;209:77-87.
PubMed Abstract available

GUIJARRO-CAMPILLO AR, Gonzalez-Gil A, Gil-Gomez E, Olivares-Ripoll V, et al
Corrigendum to "Rectosigmoidectomy versus pelvic peritonectomy in the management of seromuscular involvement of superficial rectal wall tumors in advanced-stage ovarian cancer at complete interval cytoreductive surgery" [Gynecol Oncol. 2026 Apr;207:16
Gynecol Oncol. 2026;209:75-76.
PubMed

LUKEY A, Salmanpour A, Kaur P, Berchuck A, et al
Estrogen hormone therapy use in ovarian cancer patients under age 60 at diagnosis.
Gynecol Oncol. 2026;209:69-74.
PubMed Abstract available

WAGGONER RM, Ricker CN, Nie Q, Guo XM, et al
Risk-reducing gynecologic surgery decisions in Lynch syndrome at a safety-net hospital and university medical center.
Gynecol Oncol. 2026;209:56-61.
PubMed Abstract available

GRUBE M, Ribeiro de Souza B, Neilson A, Tinker A, et al
Lymph node involvement, surgery and adjuvant treatment in primary Endometrioid Ovarian carcinoma PAtients with eaRly-stage Disease (LEOPARD) - a multinational team initiative.
Gynecol Oncol. 2026;209:48-55.
PubMed Abstract available

LUDMIR D, Huang Y, Xu X, Dioun S, et al
Impact of lymphadenectomy on survival outcomes for stage I malignant ovarian germ cell tumors.
Gynecol Oncol. 2026;209:40-47.
PubMed Abstract available

MUSA FB, Boyle TAC, Lim JT, Moore J, et al
Real-world monitoring and clinical management of decreased platelet counts in patients with epithelial ovarian cancer who received first-line maintenance niraparib in the ACTIV1ZE study.
Gynecol Oncol. 2026;209:33-39.
PubMed Abstract available

BURNS R, Esposito A, Keomany J, Okut H, et al
A comparison of vulvar surgery outcomes after prophylactic antibiotic use.
Gynecol Oncol. 2026;208:100-105.
PubMed Abstract available

NELSON OL, Rosales R, Turbov J, Thaete LG, et al
Progestin and vitamin D synergistically inhibit fallopian tube carcinogenesis.
Gynecol Oncol. 2026;208:8-16.
PubMed Abstract available

SAULE C, Laas E, Weber N, Bataillon G, et al
Peritoneal cancer risk after risk reducing salpingo-oophorectomy, impact of mutational status and STIC lesions.
Gynecol Oncol. 2026;208:1-7.
PubMed Abstract available

DAVIS JM, Dudley JC, Fader AN
Tampon-based methylated DNA testing for endometrial cancer: Promising innovation, but prudence before practice.
Gynecol Oncol. 2026;208:A1-A2.
PubMed

April 2026

SHACHAR EK, Silverstein J, Kwan L, Salani R, et al
Are patient factors associated with real-world antibody-drug conjugate outcomes in gynecologic cancers?
Gynecol Oncol. 2026;209:26-32.
PubMed Abstract available

URBAN R, Castellano T, Doll K, DeLair D, et al
Endometrial cancer: A Society of Gynecologic Oncology evidence-based review and recommendations: Part I.
Gynecol Oncol. 2026;209:15-25.
PubMed Abstract available

CAGDAS EK
Pathway-level somatic mutation burden reflects diffuse genomic accumulation rather than selective transcriptional disruption in ovarian serous carcinoma: Evidence from bulk, spatial, and multi-region genomic analyses.
Gynecol Oncol. 2026;209:7-14.
PubMed Abstract available

SORRENTINO L, Bogani G, Chiappa V, Lalli L, et al
Predictive features of anastomotic leakage after colorectal resection in complex multivisceral cytoreductive surgery for ovarian cancer.
Gynecol Oncol. 2026;209:1-6.
PubMed Abstract available

OGASAWARA A, Suzuki S, Oda K, Yunokawa M, et al
Phase II study of pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025).
Gynecol Oncol. 2026;208:122-130.
PubMed Abstract available

KIM JH, Hwang WY, Choi CH, Kim HS, et al
Oncologic outcomes and the impact of minimally invasive surgery in early-stage cervical cancer patients undergoing radical trachelectomy: A retrospective multicenter cohort study from the Korean Gynecologic Oncology Group Study (KGOG 1048).
Gynecol Oncol. 2026;208:113-121.
PubMed Abstract available

LIU JB, He TX, Zeng C, Kaur MN, et al
Association of surgical complexity with patient-reported outcomes among patients with ovarian cancer.
Gynecol Oncol. 2026;208:106-112.
PubMed Abstract available

BAKKUM-GAMEZ JN, Harrington SP, Slettedahl SW, Berger CK, et al
Optimization of methylated DNA markers to rule out endometrial cancer in patients with abnormal uterine bleeding.
Gynecol Oncol. 2026;208:91-99.
PubMed Abstract available

LEE J, Seo K, Kim J, Son JH, et al
Evaluating alternative protocols for preventing cisplatin-induced acute kidney injury during hyperthermic intraperitoneal chemotherapy in ovarian cancer.
Gynecol Oncol. 2026;208:85-90.
PubMed Abstract available

FEDERICO A, Pisano G, Fragomeni SM, Pavone M, et al
Lymphatic mapping and sentinel node biopsy in invasive Vulvar Paget's disease: A retrospective study and systematic review of the literature.
Gynecol Oncol. 2026;207:57-65.
PubMed Abstract available

HOCKEL M, Weydandt L, Wolf B, Keream EA, et al
Peripheral immune network-directed dissection of lymph node regions (iLND): Novel surgical approach for the regional assessment and therapy of vulvar carcinoma.
Gynecol Oncol. 2026;207:23-33.
PubMed Abstract available

AGUSTI N, Rauh-Hain JA
Same-day discharge in advanced ovarian cancer as a milestone of surgical evolution and patient selection.
Gynecol Oncol. 2026;207:A1-A2.
PubMed

CHALIF J, Morton M, Gonzalez A, McLaughlin E, et al
Evaluation of immunotherapy response in the radiated field in patients with recurrent endometrial and cervical cancer.
Gynecol Oncol. 2026;208:77-84.
PubMed Abstract available

PARANJPE R, Chen C, Sun Y, Hong JL, et al
Molecular heterogeneity of endometrial cancer in the real-world: Biomarker patterns by tumor stage, histology, and molecular subtype.
Gynecol Oncol. 2026;208:69-76.
PubMed Abstract available

BASHI A, Penvose KN, Wright JD, Blank SV, et al
Cost and efficiency of universal versus selective next generation sequencing for advanced stage endometrial cancer.
Gynecol Oncol. 2026;207S:67-73.
PubMed Abstract available

LEVIN G, Gilbert L, Coleman RL, Meyer R, et al
Industry payments to U.S. gynecologic oncologists: Gender, geographic, and therapeutic trends.
Gynecol Oncol. 2026;207S:60-66.
PubMed Abstract available

KRIVENKO O, Diaz N, Richardson K, Antonio D, et al
Impact of a community-centered intervention on knowledge, confidence, and attitudes toward clinical trials: A pilot survey study.
Gynecol Oncol. 2026;207S:53-59.
PubMed Abstract available

ROTHNIE K, Tristano E, Diaz-Rodriguez M, Filippova O, et al
Expanded subtype testing for circulating tumor HPV DNA reliably detects the presence of advanced-stage cervical cancer.
Gynecol Oncol. 2026;207S:47-52.
PubMed Abstract available

EPSTEIN ES, Primiano M, Ozarowski AL, Karimaghaie T, et al
ACT-ON: Assisted cascade testing via outreach and navigation - Real-world experience with clinician-facilitated cascade testing.
Gynecol Oncol. 2026;207S:38-46.
PubMed Abstract available

SAWAYA K, Maraghe M, Metzger S, Heming CM, et al
Identifying ovarian cancer with AI analysis of abdominal CT scans.
Gynecol Oncol. 2026;207S:30-37.
PubMed Abstract available

VAN NIEUWENHUYSEN E, Vergote I, Randall LM, Tromp J, et al
Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.
Gynecol Oncol. 2026;207S:3-13.
PubMed Abstract available

HSIEH TYJ, Yen TT, Hacker MR, Dottino J, et al
Impact of GLP-1 RA plus progestin therapy on fertility-sparing management of endometrial intraepithelial neoplasia and endometrial cancer.
Gynecol Oncol. 2026;207S:23-29.
PubMed Abstract available

LIU B, Chen J, Chen L, Chen X, et al
Efficacy and safety of cadonilimab combined with chemotherapy as first-line treatment for primary advanced or recurrent endometrial cancer: An interim analysis of a prospective, single-arm, open-label phase II trial.
Gynecol Oncol. 2026;207S:14-22.
PubMed Abstract available

Society of Gynecologic Oncology Annual Meeting Special Issue.
Gynecol Oncol. 2026;207S:1.
PubMed

March 2026

CHALIF J, Moruzzi C, Velasquez J, O'Connor R, et al
Implementing non-invasive biospecimen collection in gynecologic oncology: Insights from a prospective gut microbiome feasibility study.
Gynecol Oncol. 2026;208:63-68.
PubMed Abstract available

SCHREUDER GOEDHEIJT M, Aronson SL, Sonke GS, van Driel WJ, et al
Influence of cardiophrenic lymph nodes on survival in patients receiving hyperthermic intraperitoneal chemotherapy for ovarian cancer in the OVHIPEC-1 trial.
Gynecol Oncol. 2026;208:54-62.
PubMed Abstract available

KAILASAM A, De Vitis L, Murphy B, Cucinella G, et al
The progesterone paradigm: Molecular prognostication in conservative management of endometrial cancer.
Gynecol Oncol. 2026;208:48-53.
PubMed Abstract available

BORKAR SR, Tasman JG, Bakkum-Gamez JN, Cheney MC, et al
Exploring delays in primary gynecologic and breast cancer diagnosis after emergency department presentation.
Gynecol Oncol. 2026;208:41-47.
PubMed Abstract available

BOYLE SJ, Dona A, Vogel RI, Argenta P, et al
Long-term survival outcomes of robotic-assisted versus traditional laparoscopy for the treatment of stage I endometrial cancer: a National Cancer Database analysis.
Gynecol Oncol. 2026;207:66-73.
PubMed Abstract available

SALEHIPOUR D, Tadess B, Moore A, Jones T, et al
Enhancing engagement in biobanking research among Black women with endometrial cancer.
Gynecol Oncol. 2026;208:32-40.
PubMed Abstract available

ALTAYF A, Nelson G, Chiva LM, Restaino S, et al
The role of hyperthermic intraperitoneal chemotherapy in newly diagnosed and recurrent ovarian cancer: A time-to-event meta-analysis of randomized trials.
Gynecol Oncol. 2026;208:22-31.
PubMed Abstract available

FINCH L, Broach V, Long KC, Gardner GJ, et al
Noncompete agreements in job contracts: Knowledge and opinion of practicing gynecologic oncologist members of Society of Gynecologic Oncology.
Gynecol Oncol. 2026;208:17-21.
PubMed Abstract available

LEE MW, Friedman EL, Erfani H, Keymeulen S, et al
Assessment of survival and clinicopathologic characteristics associated with lymph node isolated tumor cells in epithelial ovarian cancer.
Gynecol Oncol. 2026;207:50-56.
PubMed Abstract available

NAKAYAMA J, McGaughey M, Pindzola G, Miller E, et al
Corrigendum to 'Machine-learning survival models for predicting time to recurrence in epithelial ovarian cancer' [Gynecologic Oncology 204 (2026) 184-193].
Gynecol Oncol. 2026;207:48-49.
PubMed

BOU ZERDAN M, Saab R, Meyer LA, Munsell MF, et al
Demographics, clinicopathological features, and survival outcomes of women with endometrial neuroendocrine tumors.
Gynecol Oncol. 2026;207:34-39.
PubMed Abstract available

MOREL D, Parvu V, Andrews J, Stephenson P, et al
HPV genotype prevalence in low- and high-vaccine coverage, USA populations: Data from real-world cervical cancer screening using the Onclarity HPV assay.
Gynecol Oncol. 2026;207:40-47.
PubMed Abstract available

SAAB R, Brazan A, Chisholm GB, Gonzales NR, et al
Clear cell carcinoma of cervix and vagina: A review of 63 cases in the post-DES era.
Gynecol Oncol. 2026;206:39-44.
PubMed Abstract available

FRAGOMENI SM, Collarino A, Federico A, Pisano G, et al
Extending eligibility criteria for sentinel lymph node biopsy in vulvar cancer: An update on the GroSNaPET study.
Gynecol Oncol. 2026;206:15-22.
PubMed Abstract available

DWYER E, Kennedy L, Bethune D, Katz R, et al
Granulosa cell tumors: Initial surgical approach and recurrence.
Gynecol Oncol. 2026;206:9-14.
PubMed Abstract available

ESKANDER RN, Lorusso D
Hitting the mark-or missing it? The promise and peril of biomarkers in endometrial cancer.
Gynecol Oncol. 2026;206:A1-A2.
PubMed

February 2026

GUIJARRO-CAMPILLO AR, Gonzalez-Gil A, Gil-Gomez E, Olivares-Ripoll V, et al
Rectosigmoidectomy versus pelvic peritonectomy in the management of seromuscular involvement of superficial rectal wall tumors in advanced-stage ovarian cancer at complete interval cytoreductive surgery.
Gynecol Oncol. 2026;207:16-22.
PubMed Abstract available

INAN M, Akar Inan S, Aypak C, Turkmen O, et al
Emily vs. Lakisha: Quantifying socioeconomic and structural disparities in AI-generated ovarian cancer care plans.
Gynecol Oncol. 2026;207:7-15.
PubMed Abstract available

TEWARI S, Youssef A, Li S, Stewart T, et al
Same day discharge after minimally invasive interval debulking surgery in advanced stage ovarian cancer.
Gynecol Oncol. 2026;207:1-6.
PubMed Abstract available

LEE KY, Tseng TH, Chang WC, Tai YJ, et al
Survival outcomes and time toxicity of Sandwich versus Sequential chemoradiation in Stage III endometrial cancer: A real-world study stratified by molecular classification.
Gynecol Oncol. 2026;206:117-124.
PubMed Abstract available

TALEBIAN N, Falah Tafti M, Alikarami S, Modugno F, et al
Lifetime ovulations and endometrial cancer risk: A systematic review and meta-analysis.
Gynecol Oncol. 2026;206:106-116.
PubMed Abstract available

DAIX-MOREUX M, El Hajj H, Scherier S, Deandreis D, et al
Para-aortic lymphadenectomy after negative PET-CT in locally advanced cervical cancer: a continuous monocentric series of 320 cases.
Gynecol Oncol. 2026;206:99-105.
PubMed Abstract available

BESHAR I, Khorshid A, Somasegar S, Kennedy L, et al
Pre-operative cross-sectional imaging of chest, abdomen, pelvis is not cost-effective for low-grade endometrial cancer.
Gynecol Oncol. 2026;206:93-98.
PubMed Abstract available

WANG X, Zheng L, Zhu G, Wang S, et al
CDO1 and CELF4 methylation assay as the dominant predictor of endometrial cancer: A cohort analysis across pre- and post-menopausal cohorts.
Gynecol Oncol. 2026;206:82-92.
PubMed Abstract available

DUE LP, Ketabi Z, Hogdall C, Rasmussen ELK, et al
Clinico-pathological characteristics of adult granulosa cell tumors of the ovary and the role of staging surgery: A national database study.
Gynecol Oncol. 2026;206:74-81.
PubMed Abstract available

PALMIERI L, Bellone S, Demirkiran C, Hartwich TMP, et al
Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts.
Gynecol Oncol. 2026;206:65-73.
PubMed Abstract available

WESTIN SN, Moore K, Chon HS, Pepin JT, et al
Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO- E/GOG-3041/ENGOT-EN10 trial
Gynecol Oncol. 2026;206:54-64.
PubMed Abstract available

GARKHAIL P, de Bruin PC, Boere IA, van der Aa MA, et al
Survival benefit of platinum-based chemotherapy in non-surgically treated advanced ovarian cancer: A nationwide study.
Gynecol Oncol. 2026;206:45-53.
PubMed Abstract available

HODENT S, Bakrin N, Rousset P, Kepenekian V, et al
Eco-responsible and rational interval debulking surgery for high-grade ovarian carcinomas: An observational, ambispective cohort study.
Gynecol Oncol. 2026;206:32-38.
PubMed Abstract available

VERMAAS EM, Wenzel HHB, van der Aa MA, Snijders M, et al
Impact of COVID-19 on oncological outcomes during follow-up in gynaecological cancer: A nationwide retrospective cohort study.
Gynecol Oncol. 2026;205:79-88.
PubMed Abstract available

NAUMANN RW
Commentary on: Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup Canadian Cancer Trials Group Cx.5/SHAPE tr
Gynecol Oncol. 2026;205:A1-A2.
PubMed

January 2026

SHERMAN ME, Pacheco-Spann L, Friedman S, Rose D, et al
BRCA1 and BRCA2 carriers: Perceptions of endometrial cancer risk.
Gynecol Oncol. 2026;206:23-31.
PubMed Abstract available

PEREZ L, Kulkarni A, Lopez S, Brewer JT, et al
Understanding patient priorities: Sexual health and hereditary ovarian cancer syndromes.
Gynecol Oncol. 2026;205:113-119.
PubMed Abstract available

MATTHEWS BJ, Paskett ED, McLaughlin E, Von Ah D, et al
Risk of memory impairment in gynecologic cancer survivors in the Women's Health Initiative: Untangling effects of age, comorbidities, and cancer.
Gynecol Oncol. 2026;206:1-8.
PubMed Abstract available

JAMIESON A, Rogan S, Zhang AW, Martin SD, et al
Substratification of mismatch repair deficient endometrial cancers based on mechanism of MMR loss can provide prognostic and predictive refinement.
Gynecol Oncol. 2026;205:105-112.
PubMed Abstract available

BRODSKY AL, Tahan E, Celestino J, Tang X, et al
Expression of antibody drug conjugate target antigens in ovarian sex cord stromal Tumors.
Gynecol Oncol. 2026;205:99-104.
PubMed Abstract available

WOHLRAB K, Robison K, Rahn DD, Dunivan GC, et al
Safety and feasibility of concomitant urogynecologic and gynecologic oncology surgical procedures.
Gynecol Oncol. 2026 Jan 22:S0090-8258(26)00007.
PubMed Abstract available

JAIN D, Wahidi M, Effendi J, Hoang L, et al
Survival comparison analysis between cervical squamous cell carcinoma and adenocarcinoma with a special focus on the HPV status.
Gynecol Oncol. 2026;205:89-98.
PubMed Abstract available

ROTHSCHILD H, Hillman RT
New therapeutic strategies for relapsed adult type ovarian granulosa cell Tumors: From discovery to clinical progress.
Gynecol Oncol. 2026 Jan 19:S0090-8258(26)00011.
PubMed

LINZ VC, Liebau E, Herrmann L, Schepers M, et al
Association of preoperative G8 score with survival, preoperative anemia and vitamin D status in gynecologic cancer patients: 5-year analysis of the Frail-B study.
Gynecol Oncol. 2026;205:70-78.
PubMed Abstract available

SEERATAN DD, Jongkind A, van Lonkhuijzen LRCW, van Muilekom MM, et al
Utilization of patient-reported outcome measures for women with low health literacy in gynecologic oncology - A mixed-methods study.
Gynecol Oncol. 2026;205:53-62.
PubMed Abstract available

CUTRI-FRENCH C, Saris DH, Solorzano SS, Wang X, et al
Disparities in access to gynecologic oncology visits among elderly patients with gynecologic malignancies.
Gynecol Oncol. 2026;205:63-69.
PubMed Abstract available

MORGAN JE, Chen L, Xu X, Dioun S, et al
Trends, predictors, and safety of ovarian preservation in premenopausal women with high-grade endometrioid and non-endometrioid endometrial cancers.
Gynecol Oncol. 2026;205:46-52.
PubMed Abstract available

KIM SI, Kim JW, Kwon JS, Ferguson SE, et al
Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial.
Gynecol Oncol. 2026;205:37-45.
PubMed Abstract available

PARULEKAR M, Kim YN, Kim K, Lee S, et al
Leveraging tumor multigene panel testing to identify germline variants in gynecologic cancers: A retrospective evaluation of an algorithm-based approach.
Gynecol Oncol. 2026;205:32-36.
PubMed Abstract available

SMITH HJ, Dinkins K, Liang MI, Chu DI, et al
Feasibility of a mobile health platform for patient education and remote symptom monitoring in patients with advanced ovarian cancer undergoing primary chemotherapy.
Gynecol Oncol. 2026;205:27-31.
PubMed Abstract available

TANG W, Wang L, Li X, Yan X, et al
Radiation-induced acquired expression of PD-L1 and reprogramming of the tumor microenvironment in cervical cancer.
Gynecol Oncol. 2026;205:17-26.
PubMed Abstract available

FAN KY, Chehade R, Wang AY, Sachdeva A, et al
Surgery versus definitive radiotherapy in the management of stage I-II small cell neuroendocrine carcinoma of the cervix: A systematic review and meta-analysis.
Gynecol Oncol. 2026;204:118-123.
PubMed Abstract available

RHIND M, Abdulhaleem K, Zhu R, Wei K, et al
Exploring novel therapeutic targets in vulvar squamous cell carcinoma.
Gynecol Oncol. 2026;204:63-69.
PubMed Abstract available

DING M, Li X, Wang H, Jia X, et al
G-M6, an oleanane triterpenoid, represents a novel scaffold for PARP1 inhibition and anticancer activity.
Gynecol Oncol. 2026;204:9-16.
PubMed Abstract available

ANNUNZIATA CM
Towards personalizing PARP inhibitor maintenance therapy for ovarian cancer.
Gynecol Oncol. 2026;204:A1-A2.
PubMed

December 2025

LUDMIR D, Huang Y, Xu X, Dioun S, et al
Utilization and outcomes of fertility-sparing ovarian cystectomy for stage I malignant ovarian germ cell tumors.
Gynecol Oncol. 2025;205:9-16.
PubMed Abstract available

AHMED A, Saini G, Ferguson SE, Fazelzad R, et al
Prognostic value of perioperative circulating tumor DNA in endometrial cancer: systematic review & meta-analysis.
Gynecol Oncol. 2025;205:1-8.
PubMed Abstract available

LESNOCK J, Gaillard S, Tew WP
ASCO neoadjuvant chemotherapy in ovarian cancer guideline: A SGO endorsement.
Gynecol Oncol. 2025;204:251-253.
PubMed

LIM JW, Drost L, Fazelzad R, Li Q, et al
MLH1 promoter hypermethylated endometrial cancer survival outcomes: A systematic review and meta-analysis.
Gynecol Oncol. 2025;204:242-250.
PubMed Abstract available

MAESTA I, Silva VAR, Costa RAA, Carvalho TH, et al
Home-based treatment of low-risk gestational trophoblastic neoplasia with 8-day methotrexate/folinic acid.
Gynecol Oncol. 2025;204:235-241.
PubMed Abstract available

PATTERSON B, Sinha N, Broaddus E, Stocks S, et al
Associations between obesity and outcomes in pembrolizumab-treated endometrial cancer.
Gynecol Oncol. 2025;204:228-234.
PubMed Abstract available

WASHINGTON C, Pothuri B, Cadoo K, Drew Y, et al
Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review.
Gynecol Oncol. 2025;204:218-227.
PubMed Abstract available

FERNANDES I, Sachdeva A, Tavangar F, Lafreniere M, et al
Evaluating the clinical utility and impact on healthcare utilization of serial troponin T monitoring in gynecologic cancer patients receiving immune checkpoint inhibitors - A single centre experience.
Gynecol Oncol. 2025;204:210-217.
PubMed Abstract available

SHAHIN MS, Mathur R, Parthan A, Yerram P, et al
Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS).
Gynecol Oncol. 2025;204:202-209.
PubMed Abstract available

PEPLINSKI RM, Riordan JD, Schillo JL, Hannan EC, et al
Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell lines.
Gynecol Oncol. 2025;204:194-201.
PubMed Abstract available

NAKAYAMA J, McGaughey M, Pindzola G, Miller E, et al
Machine-learning survival models for predicting time to recurrence in epithelial ovarian cancer.
Gynecol Oncol. 2025;204:184-193.
PubMed Abstract available

EVANS HE, Firriolo AM, Houweling R, Kelada L, et al
Evaluating patient perspectives about the acceptability of a novel prognostic gene expression signature for high grade serous ovarian cancer: The OTTA-SPOT study.
Gynecol Oncol. 2025;204:150-157.
PubMed Abstract available

MATSUO K, Lee MW, Friedman EL, Erfani H, et al
Survival assessment of sentinel lymph node biopsy alone without lymphadenectomy for early cervical cancer in real-world data.
Gynecol Oncol. 2025;204:174-183.
PubMed Abstract available

LIM S, Chung YE, Seo JH, Lee Y, et al
Efficacy and safety of pembrolizumab with or without lenvatinib in recurrent uterine carcinosarcoma: a real-world single-center study.
Gynecol Oncol. 2025;204:165-173.
PubMed Abstract available

WANG Y, Van Nieuwenhuysen E, Revheim ME, Deroose CM, et al
First experience with intraperitoneal (224)Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer.
Gynecol Oncol. 2025;204:158-164.
PubMed Abstract available

HANSEN J, Suratkal J, Shah SN, Kelley J, et al
Frailty and body composition as predictors of postoperative outcomes in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy.
Gynecol Oncol. 2025;204:143-149.
PubMed Abstract available

KRAICZY J, Yu B
Human fallopian tube epithelial organoids with TP53 mutation recapitulate features of serous tubal intraepithelial carcinoma (STIC).
Gynecol Oncol. 2025;203:198-208.
PubMed Abstract available

LU H, Wang Y, Chang L, Liu J, et al
Treatment patterns and prognosis of patients with locally advanced vulvar cancer: a retrospective cohort study of the SEER database and a Chinese multicenter registry.
Gynecol Oncol. 2025;203:171-181.
PubMed Abstract available

VERMAAS EM, Roling P, Konior KM, Wenzel HHB, et al
Reconsidering follow-up care in gynaecologic oncology: A scoping review exploring alternative approaches.
Gynecol Oncol. 2025;203:139-150.
PubMed Abstract available

FAN Y, Wang Q, Deng H, Liu Y, et al
Neoadjuvant chemotherapy modulates mast cell phenotypes and immune infiltration in high-grade serous carcinoma.
Gynecol Oncol. 2025;203:119-129.
PubMed Abstract available

DHANIS J, Pijnenborg JMA, van Laarhoven CJHM, Verlaan S, et al
The effect of a multimodal prehabilitation programme on preoperative physical fitness and nutritional status of women with gynaecological cancer.
Gynecol Oncol. 2025;203:1-7.
PubMed Abstract available

NISHA M, Liang YL, Bateson D, Saville M, et al
Optimising management of women with HPV (not 16/18): Findings from a national HPV screening program.
Gynecol Oncol. 2025;204:133-142.
PubMed Abstract available

November 2025

JOHNSON RL, Mappa G, Gahir N, Allen KE, et al
Prognostic and immunological significance of tryptophan metabolic enzymes across endometrial cancer molecular subtypes.
Gynecol Oncol. 2025;204:124-131.
PubMed Abstract available

SALANI R, Atallah D, Fader AN, Frimer M, et al
Updates to post-treatment surveillance after curative intent treatment for patients with gynecologic cancers: A Society of Gynecologic Oncology clinical practice statement.
Gynecol Oncol. 2025;204:109-117.
PubMed Abstract available

SOPPE SE, Kuo TM, Lyratzopoulos G, DeRouen MC, et al
Symptom-related care and diagnoses before ovarian cancer detection: Patterns and differences by cancer stage.
Gynecol Oncol. 2025;204:100-108.
PubMed Abstract available

EVERT JSH, de Jonge PKJD, Zusterzeel PLM, Hobo W, et al
Intraperitoneal infusion of stem cell-derived natural killer cells in recurrent epithelial ovarian cancer patients: Results of the phase 1 INTRO-01 trial.
Gynecol Oncol. 2025;204:91-99.
PubMed Abstract available

CUN HT, Bedell SM, Kimball J, Gaffney DK, et al
Radiation therapy for the gynecologic oncologist.
Gynecol Oncol. 2025;204:79-90.
PubMed Abstract available

HAYAKAWA M, Nakajima H, Harano K, Watanabe S, et al
Impact of platinum-free interval and bevacizumab on second-line chemotherapy following progression on first-line PARP inhibitor maintenance in advanced ovarian cancer: A retrospective cohort study.
Gynecol Oncol. 2025;204:70-78.
PubMed Abstract available

TANKOU J, Ruau S, Walia A, Toboni M, et al
AXL inhibition improves the therapeutic efficacy of trastuzumab in high-risk endometrial cancer.
Gynecol Oncol. 2025;204:52-62.
PubMed Abstract available

SHI Y, Gkekos L, Rodriguez-Wallberg KA, Fredriksson I, et al
Obstetric and perinatal outcomes following a diagnosis of gynecologic cancer during pregnancy.
Gynecol Oncol. 2025;204:44-51.
PubMed Abstract available

TOBONI MD, Evans ET, Scalise CB, Hardesty M, et al
Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize treatment?
Gynecol Oncol. 2025;204:37-43.
PubMed Abstract available

LEE AJ, Jang EB, Suh DH, Chang SJ, et al
Comparison of oncologic outcomes between completion hysterectomy and no completion hysterectomy in patients who achieved complete response and completed childbearing after fertility-sparing treatment for early-stage endometrial cancer: Gynecologic Onc
Gynecol Oncol. 2025;203:191-197.
PubMed Abstract available

BAO W, He X, Huang Y, Xing A, et al
Effect of uterine manipulator on stage IB1 to IIA1 cervical cancer: A retrospective cohort study.
Gynecol Oncol. 2025;204:27-36.
PubMed Abstract available

ARIOLA AB, Nolan B, Johnson L, Cunningham MJ, et al
The impact of cervical diameter on success of sentinel lymph node mapping in endometrial carcinoma: A retrospective cohort study.
Gynecol Oncol. 2025;204:23-26.
PubMed Abstract available

FURUYA RL, Grither W, Evans MG, Wu S, et al
Comparison of breast and gastric HER2 immunohistochemistry (IHC) scoring criteria in the assessment of endometrial carcinoma.
Gynecol Oncol. 2025;204:17-22.
PubMed Abstract available

ARYASOMAYAJULA C, Johnson CR, Francoeur AA, Sia TY, et al
Pathogenic germline variants among patients with ovarian cancer by self-reported ancestry: A commercial laboratory collaborative research registry study.
Gynecol Oncol. 2025;204:1-8.
PubMed Abstract available

CHUNG YE, Kim SI, Noh JJ, Lee JY, et al
Immune checkpoint inhibitors for recurrent ovarian clear cell carcinoma: Real-world outcomes from a Korean multicenter study.
Gynecol Oncol. 2025;203:185-190.
PubMed Abstract available

CORTES-SALGADO A, Moreno-Moreno E, Carretero-Barrio I, Caniego-Casas T, et al
Corrigendum to 'HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study' [Gynecologic Oncology 194 (2025) 33-40].
Gynecol Oncol. 2025;203:184.
PubMed

THAKER PH, Richardson DL, Hagemann AR, Holloway RW, et al
Corrigendum to 'OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer' [Gynecol Oncol 2025 Jun 19
Gynecol Oncol. 2025;203:182-183.
PubMed

TISCHER KM, Islam NS, McGree ME, Tapia AL, et al
Quantifying opportunities to reduce high grade serous ovarian cancer via opportunistic salpingectomy.
Gynecol Oncol. 2025;203:165-170.
PubMed Abstract available

WASHINGTON C, Dwivedi SKD, Gunderson-Jackson C, Walker J, et al
Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary.
Gynecol Oncol. 2025;203:158-164.
PubMed Abstract available

PARK J, Lee D, Kim S, Kim YN, et al
Prognostic implications of HER2 in ovarian cancer: Associations with homologous recombination deficiency and folate receptor alpha expression.
Gynecol Oncol. 2025;203:151-157.
PubMed Abstract available

BASHI A, Chen L, Rouse K, Elkin EB, et al
Cost-effectiveness of biomarker-based and universal strategies for the treatment of advanced-stage endometrial cancer.
Gynecol Oncol. 2025;203:130-138.
PubMed Abstract available

DRAYER SM, Ogata JD, Cronin S, Tumas J, et al
Silva pattern-guided proteomics reveals coordinated tumor-stroma remodeling in cervical adenocarcinoma.
Gynecol Oncol. 2025;202:66-76.
PubMed Abstract available

MILMAN T, Hoang L, Hamm J, Chai J, et al
Real-world utility of Silva pattern in predicting outcomes in cervical adenocarcinoma from a population-based series.
Gynecol Oncol. 2025;202:53-58.
PubMed Abstract available

HUANG M, McCourt C, Powell MA, Lu KH, et al
Amplifying SGO'S voice: The impact of the Society of Gynecologic Oncology (SGO) clinical practice committee publications in Gynecologic Oncology.
Gynecol Oncol. 2025;202:A1-A2.
PubMed

October 2025

MOUFARRIJ S, Friedman CF, Freeman S, Green H, et al
A pilot study of nivolumab in combination with neoadjuvant and post-surgical chemotherapy in newly diagnosed ovarian cancer.
Gynecol Oncol. 2025;203:97-104.
PubMed Abstract available

WHITE VM, Langdale LM, Eroh KD, Ackermann MK, et al
Experiences of radiotherapy for treatment of Granulosa Cell Tumor of the ovary: insights from the GCT-survivor sisters.
Gynecol Oncol. 2025;203:112-118.
PubMed Abstract available

NOZAKI T, Sakamoto I, Kagami K, Matsuda K, et al
Preoperative molecular classification of endometrial cancer: Validation through biopsy and matched hysterectomy specimens.
Gynecol Oncol. 2025;203:105-111.
PubMed Abstract available

LINDGREN A, Benseler A, Hogen L, May T, et al
Description of first recurrence in advanced stage high grade serous ovarian cancer receiving intraperitoneal versus intravenous systemic treatment.
Gynecol Oncol. 2025;203:90-96.
PubMed Abstract available

ARAUJO LW, Maliniak ML, Barber LE, Dilley SE, et al
Neighborhood socioeconomic status and endometrial cancer mortality: Racial disparities persist across the spectrum.
Gynecol Oncol. 2025;203:84-89.
PubMed Abstract available

XU X, Chen L, Nunez-Smith M, Clark M, et al
Postmenopausal bleeding: Association of initial place of care with stage at diagnosis for uterine cancer.
Gynecol Oncol. 2025;203:75-83.
PubMed Abstract available

WANG Y, Li J, Yang Y, Lu X, et al
Letrozole plus anlotinib as a chemotherapy-free regimen for ER-positive platinum-resistant recurrent epithelial ovarian cancer patients following second-line platinum-based chemotherapy failure: A prospective, single-arm, open-label, phase II study.
Gynecol Oncol. 2025;203:67-74.
PubMed Abstract available

SKOLD C, Radestad AF, Bohlin KS, Bjurberg M, et al
Primary treatment and survival in malignant ovarian germ cell tumors: A nationwide population-based Swedish Gynecologic Cancer Group (SweGCG) study.
Gynecol Oncol. 2025;203:59-66.
PubMed Abstract available

TEWARI S, Koelker-Wolfe E, Pelletier A, St Laurent J, et al
The impact of romiplostim use for chemotherapy induced thrombocytopenia on immediate and long-term outcomes in gynecologic malignancies.
Gynecol Oncol. 2025;203:53-58.
PubMed Abstract available

ANDRES S, Tannous A, Kahn RM, Yeoshoua E, et al
Survival outcomes in patients receiving neoadjuvant chemotherapy for advanced ovarian cancer: Does the indication for neoadjuvant chemotherapy matter?
Gynecol Oncol. 2025;203:35-42.
PubMed Abstract available

MANNING B, Banerjee S, Hawkins TB, Winn-Deen ES, et al
Extracellular vesicle and particle-based blood test for ovarian cancer screening of average risk population: a promising nested case control study using preclinical samples.
Gynecol Oncol. 2025;203:26-34.
PubMed Abstract available

MACHIDA H, Kawana K, Okamoto A, Yamagami W, et al
Impact of neoadjuvant chemotherapy followed by interval debulking surgery on survival in women with advanced non-serous ovarian, fallopian tube, or primary peritoneal cancer.
Gynecol Oncol. 2025;203:8-15.
PubMed Abstract available

HOTTON J, Gaillard T, Paoletti X, Raimond E, et al
Survival impact of residual disease and timing of surgery in the management of advanced-stage low grade serous ovarian cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2025;203:16-25.
PubMed Abstract available

MAURER T, Belau MH, Zyriax BC, Welsch G, et al
Development and optimization of an integrated exercise and nutrition program for ovarian cancer patients: Phase I of the BENITA multi-center study.
Gynecol Oncol. 2025;202:167-173.
PubMed Abstract available

HOLTZMAN S, Myers E, Havrilesky LJ, Yamada D, et al
Gynecologic oncology fellowship trends: Supply outpacing demand, geographical maldistribution.
Gynecol Oncol. 2025;202:162-166.
PubMed Abstract available

DAGHER C, Selenica P, Bakhuis CFJ, Green H, et al
Prognostic value of positive peritoneal cytology in FIGO 2009 stage IA grade 1 endometrioid endometrial cancer.
Gynecol Oncol. 2025;202:154-161.
PubMed Abstract available

KIM U, Oh BC, Bae J, Kang S, et al
Survival outcomes and treatment patterns in malignant ovarian sex cord-stromal tumors: A population-based analysis.
Gynecol Oncol. 2025;202:146-153.
PubMed Abstract available

POWELL CA, Winer IS, Tarney CM, Gaillard S, et al
Interstitial lung disease in targeted therapies: A Society of Gynecologic Oncology clinical practice statement.
Gynecol Oncol. 2025;202:137-145.
PubMed Abstract available

ETTORRE VM, Bellone S, Buza N, Hui P, et al
Immunohistochemistry, next generation sequencing (NGS), and whole exome sequencing concordance in HER2 testing in uterine serous carcinoma: a retrospective analysis.
Gynecol Oncol. 2025;202:131-136.
PubMed Abstract available

BORDEN BA, Rodriguez-Hernandez A, Trottier M, Horiguchi M, et al
SMARCA4 pathogenic variants: Gynecological cancer histories from a laboratory tested cohort.
Gynecol Oncol. 2025;202:125-130.
PubMed Abstract available

KOCIAN R, Kohler C, Klat J, Jarkovsky J, et al
Sentinel lymph node mapping in early-stage cervical cancer: Results from the SENTIX prospective multicenter study.
Gynecol Oncol. 2025;202:118-124.
PubMed Abstract available

GARG V, Armstrong E, Celeste A, Wang C, et al
Multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program in patients with advanced gynecological cancers: A prospective study.
Gynecol Oncol. 2025;202:110-117.
PubMed Abstract available

LIM JW, Dzyubak O, Moshkovich M, Maganti M, et al
Impact of FIGO 2023 staging criteria on stage migration and survival outcomes in early-stage endometrial cancer: A retrospective cohort study.
Gynecol Oncol. 2025;202:93-101.
PubMed Abstract available

CHASE DM, Huang HQ, Deng W, Koh WJ, et al
Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-026
Gynecol Oncol. 2025;202:102-109.
PubMed Abstract available

NEPHEW KP, Drapkin R, Lang J, Zhuravlev Y, et al
The 15th Biennial Rivkin Center ovarian cancer research symposium.
Gynecol Oncol. 2025;201:A1-A2.
PubMed Abstract available

KHADRAOUI W, Felix AS, Meade CE, Chalif J, et al
Prognostic and demographic patterns in serous tubal intraepithelial carcinoma: A National Cancer Database study.
Gynecol Oncol. 2025;201:76-82.
PubMed Abstract available

BLANK SV, Frey MK
Does a diagnosis of breast cancer reduce ovarian cancer risk in BRCA1/2 3 carriers: Why is this a question?
Gynecol Oncol. 2025;201:A3-A4.
PubMed

September 2025

JANKE MJ, Minns A, Pesce MM, McLaughlin HD, et al
Trends in pre-fellowship research productivity among matched gynecologic oncology fellows.
Gynecol Oncol. 2025;202:87-92.
PubMed Abstract available

GERSHENSON DM, Burns K, Sun C
Update on contemporary treatment for newly diagnosed stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC).
Gynecol Oncol. 2025;202:85-86.
PubMed

SIA TY, Brown DN, Miller K, Curtin C, et al
Uterine leiomyosarcoma progression: A study of serial recurrences.
Gynecol Oncol. 2025;202:77-84.
PubMed Abstract available

SOMASEGAR S, Zhang J, Fotopoulou C, Fumagalli D, et al
The role of neoadjuvant chemotherapy in advanced-stage clear cell ovarian cancer: A GCIG multi-institutional retrospective cohort study.
Gynecol Oncol. 2025;202:59-65.
PubMed Abstract available

GENG F, Wang Y, Cui G, Fan M, et al
TRIB3 promotes endometrial cancer progression through interacting with E2F1 and enhancing PKM2-mediated tumor glycolysis.
Gynecol Oncol. 2025;202:41-52.
PubMed Abstract available

AN J, Li G, Zhang Y, Feng M, et al
Sacituzumab govitecan in Chinese patients with recurrent/metastatic cervical cancer: Results from the phase 2 EVER-132-003 basket study (NCT05119907).
Gynecol Oncol. 2025;202:33-40.
PubMed Abstract available

SUGIYAMA Y, Kosugi M, Gotoh O, Tonooka A, et al
Genomic and DNA methylomic factors associated with the efficacy of oral medroxyprogesterone acetate on endometrial neoplastic disease.
Gynecol Oncol. 2025;202:24-32.
PubMed Abstract available

YOH K, Desai VB, Gross CP, Spatz ES, et al
Physician variation in adopting opportunistic salpingectomy at the time of postpartum and interval sterilization for ovarian cancer risk reduction.
Gynecol Oncol. 2025;202:1-13.
PubMed Abstract available

VAN DEN BORST E, Vanden Broeck D, De Sutter P, Donders G, et al
EUROArray HPV test accuracy for cervical precancer in self- vs. clinician-collected samples using the VALHUDES protocol.
Gynecol Oncol. 2025;202:14-23.
PubMed Abstract available

LOUKOVAARA M, Pasanen A, Butzow R
Distinct clinical outcomes according to molecular subgroups in relapsed endometrial carcinoma: A cohort study.
Gynecol Oncol. 2025;201:216-222.
PubMed Abstract available

ACKROYD SA, Sudilovsky G, Che Y, Wesevich A, et al
Race and neighborhood disadvantage in patients with stage I-III endometrioid endometrial carcinoma treated at a tertiary referral center.
Gynecol Oncol. 2025;201:203-209.
PubMed Abstract available

FULGIONE C, Inzani F, Raffone A, Raimondo D, et al
Prognosis of HPV-independent, p53-wild-type vulvar squamous cell carcinoma: A systematic review and meta-analysis.
Gynecol Oncol. 2025;201:210-215.
PubMed Abstract available

ETTORRE VM, Demirkiran C, Bellone S, Hartwich TMP, et al
Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts.
Gynecol Oncol. 2025;201:195-202.
PubMed Abstract available

MATSUO K, Enserro DM, Wright JD, Roman LD, et al
Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol.
Gynecol Oncol. 2025;201:184-194.
PubMed Abstract available

LIN Z, Liu Z, Chen J, Gu H, et al
Novel anatomical concept and standardized technique for single-port Paraaortic lymphadenectomy in gynecological cancers.
Gynecol Oncol. 2025;201:176-183.
PubMed Abstract available

REBOUILLAT C, Pomel C, Bourdel N, Mimoun C, et al
Diagnostic laparoscopy and cytoreduction surgery in ovarian cancer FIGO III-IV: The impact on survival of one-stage versus two-stage sequence.
Gynecol Oncol. 2025;201:167-175.
PubMed Abstract available

CHIAPPINELLI KB, Christie EL, Padmanabhan A
Biology of ovarian cancer: Models, microenvironment, and therapeutics: 15th Biennial Rivkin Center Ovarian Cancer Research Symposium.
Gynecol Oncol. 2025;201:160-163.
PubMed Abstract available

ZHOU N, Beavis AL, Lin LL, Neibart SS, et al
Embracing and implementing the WHO cervical cancer elimination campaign goals: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS on minimum quality care standards for cervical cancer patients in the U.S.
Gynecol Oncol. 2025;200:193-202.
PubMed Abstract available

NEIBART S, Zhou N, Chino J, Earles T, et al
Health equity, disparities, and barriers to cervical cancer care in the U.S.: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS addressing the WHO cervical Cancer elimination campaign goals related to treatment.
Gynecol Oncol. 2025;200:186-192.
PubMed Abstract available

NEIBART SS, Lin LL, Einstein MH, Teoh D, et al
Minimum standards for radiation therapy in the treatment of cervical cancer in the U.S.: A consensus statement by SGO, ASTRO, and ABS addressing the WHO Cervical Cancer Elimination Campaign goals.
Gynecol Oncol. 2025;200:180-185.
PubMed Abstract available

MATSUBARA M, Otani T, Kawakami F, Koike A, et al
Cervical adenocarcinoma risk stratification using histotype and invasion pattern: a multicenter retrospective study by the KAMOGAWA Study Group.
Gynecol Oncol. 2025;200:112-121.
PubMed Abstract available

SCHAAFSMA M, Schuurman TN, Bekkers RLM, Dunne FR, et al
The risk for residual AIS/CIN3+ after the first conservative surgical procedure for cervical adenocarcinoma in situ - A Dutch retrospective cohort study.
Gynecol Oncol. 2025;200:44-50.
PubMed Abstract available

JAEGER A, Hampl M, Prieske K, Eulenburg C, et al
Risk for non-sentinel metastases in the contralateral groin in patients with a unilateral positive sentinel lymph node in primary vulvar cancer- a subgroup analysis of the AGO-VOP.2 QS Vulva Study.
Gynecol Oncol. 2025;200:8-13.
PubMed Abstract available

MULLEN MM, Arend RC
From one-size-fits all to biology-driven care: Emerging paradigms in gynecologic oncology.
Gynecol Oncol. 2025;200:A1-A2.
PubMed

August 2025

BRODSKY AL, Welte T, Vuttaradhi VK, Yang X, et al
Efficacy of cyclin-dependent kinase 4/6 inhibitors in preclinical adult-type ovarian granulosa cell tumor models.
Gynecol Oncol. 2025;201:152-159.
PubMed Abstract available

MORTON M, Chalif J, Sciuva J, Fulton J, et al
The price of delay: Insurance-related treatment delays in patients with gynecologic cancer receiving immunotherapy.
Gynecol Oncol. 2025;201:144-151.
PubMed Abstract available

BRUCE KH, Xu C, Shah RP, McGree ME, et al
Real-world outcomes of neoadjuvant chemotherapy for advanced ovarian cancer: What happens to patients who never undergo surgery?
Gynecol Oncol. 2025;201:137-143.
PubMed Abstract available

ANDRES S, Brown DN, Da Cruz Paula A, Aghajanian C, et al
Whole-genome sequencing-based characterization of endometrial serous carcinoma.
Gynecol Oncol. 2025;201:130-136.
PubMed Abstract available

CHERRY DR, Gupta V, Bloom JR, Hsieh K, et al
Early-stage uterine papillary serous carcinoma: Clinical outcomes in patients treated with adjuvant chemotherapy and vaginal brachytherapy.
Gynecol Oncol. 2025;201:123-129.
PubMed Abstract available

SMITH AJ, Acharya R, Ang L, Moore T, et al
"What you're hearing from all of us is simplify the language": Patient perspectives on biomarker testing in ovarian cancer.
Gynecol Oncol. 2025;201:118-122.
PubMed Abstract available

SOONG TR, Islam BN, Hunt K, Nadeem A, et al
Research is care: How patients and researchers can work together to bring the bedside back to the bench - a patient advocacy panel discussion: 15th Biennial Rivkin Center Ovarian Cancer Research Symposium.
Gynecol Oncol. 2025;201:114-117.
PubMed Abstract available

PERELMUTER S, Leung AC, Ahsan MD, Webster EM, et al
Virtual versus reality: Assessing the accuracy of a digital cancer risk assessment tool in a gynecologic oncology clinic.
Gynecol Oncol. 2025;200:169-174.
PubMed Abstract available

LANITI DD, Verma P
State-of-the art in emerging therapeutics for ovarian cancer therapy.
Gynecol Oncol. 2025;201:109-113.
PubMed Abstract available

ZHANG N, Porter RL
Emerging approaches to enhance immune responses in ovarian cancer: 15th biennial Rivkin Center Ovarian Cancer Research Symposium.
Gynecol Oncol. 2025;201:97-101.
PubMed Abstract available

GAILLARD S, Alvarez J, Zhang T, Wang H, et al
A randomized pilot study of HPV16 L2E7E6 fusion protein vaccination site post-treatment for HPV16+ cervical cancer.
Gynecol Oncol. 2025;201:86-96.
PubMed Abstract available

SOZEN H, Minareci Y, Toyran A, Tutar E, et al
Evaluation of total retroperitoneal en-bloc resection of multivisceral-peritoneal packet (TROMP) in advanced ovarian cancer: A single-center cohort study.
Gynecol Oncol. 2025;201:102-108.
PubMed Abstract available

ROBIN TP, Hu J, Jones BL, Patton T, et al
Phase I trial of stereotactic body radiation therapy (SBRT) for limited site locoregional recurrences of ovarian cancer.
Gynecol Oncol. 2025;200:175-179.
PubMed Abstract available

GASPAR-MAIA A, Sasamoto N
Prevention, early detection & interception: 15th biennial ovarian cancer research symposium.
Gynecol Oncol. 2025;201:83-85.
PubMed Abstract available

CORR BR, Thomas SM, Haight PJ, Stock E, et al
Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability.
Gynecol Oncol. 2025;201:69-75.
PubMed Abstract available

SIA TY, Moufarrij S, Milani J, Kane S, et al
Germline landscape of high grade serous ovarian cancer across age groups: Is age just a number?
Gynecol Oncol. 2025;201:60-68.
PubMed Abstract available

BRUBAKER LW, Merritt MA
Ovarian cancer health disparities: 15th Biennial Rivkin Center Ovarian Cancer Research Symposium.
Gynecol Oncol. 2025;201:56-59.
PubMed Abstract available

FITCH KC, Previs RA, Moss HA
The promise and perils of biomarker testing in gynecologic cancers.
Gynecol Oncol. 2025;201:53-55.
PubMed

APOSTOL AI, Kotsopoulos J, Gronwald J, Kim RH, et al
Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant.
Gynecol Oncol. 2025;201:44-52.
PubMed Abstract available

NG ZY, McCluggage WG, Dundr P, Borcinova M, et al
Evaluation of the significance of isolated tumor cells in gynecological cancers.
Gynecol Oncol. 2025;201:40-43.
PubMed Abstract available

POLEN-DE CL, Giannini A, Langstraat CL, Moreno AG, et al
Effect of conization, manipulator use, and their interaction on recurrence after radical hysterectomy for cervical cancer: A multicenter retrospective analysis.
Gynecol Oncol. 2025;201:33-39.
PubMed Abstract available

TOWNER M, Grace A, Marcus J
Beating cancer while building families: A mixed methods study on parenting, life choices, and career trajectories of gynecologic oncologists in the United States.
Gynecol Oncol. 2025;201:26-32.
PubMed Abstract available

CHATOR C, Chevrier M, Frenel JS, Guyon F, et al
Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian Database.
Gynecol Oncol. 2025;201:17-25.
PubMed Abstract available

SPENARD E, Lin Y, Covens A, Gien LT, et al
Optimizing the screening and management of preoperative anemia prior to gynecologic oncology surgery (OPRA1): A quality improvement initiative.
Gynecol Oncol. 2025;201:7-16.
PubMed Abstract available

HACKER KE, A Fleming K, Gupta M, Pothuri B, et al
HER2 expression in an endometrial cancer cohort.
Gynecol Oncol. 2025;201:1-6.
PubMed Abstract available

BOGANI G, Fagotti A, Chiantera V, De Iaco P, et al
The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
Gynecol Oncol. 2025;200:161-168.
PubMed Abstract available

WANG Y, Jia Z, Jiao J, Yue X, et al
Analysis of the use of prophylactic ureteral stents in preventing iatrogenic ureteral injury during radical hysterectomy for cervical Cancer.
Gynecol Oncol. 2025;200:155-160.
PubMed Abstract available

MARCHETTI M, Vezzaro T, Carollo M, Facchetti E, et al
The challenge of molecular stratification in No Specific Molecular Profile endometrial cancer.
Gynecol Oncol. 2025;200:145-154.
PubMed Abstract available

CLARKE MA, Wentzensen N, Kobel M, Erickson BK, et al
Age-specific incidence and five-year relative survival of endometrial cancer histotypes by race and ethnicity among US women, 2000 to 2019.
Gynecol Oncol. 2025;200:137-144.
PubMed Abstract available

RISHI A, Albuquerque KV, Jhingran A, Donovan EK, et al
Definitive intensity-modulated radiotherapy for organ preservation in vulvar cancer: A multicenter study.
Gynecol Oncol. 2025;199:1-9.
PubMed Abstract available

July 2025

BRODSKY AL, Sun C, Cobb L, Westin SN, et al
Ovarian mixed low- and high-grade serous carcinoma as a synchronous or metachronous phenomenon: A clinicopathologic study of 39 cases.
Gynecol Oncol. 2025;200:130-136.
PubMed Abstract available

WANG JY, Simons EJ, Dingel A, Pike MM, et al
Impact of chemotherapy provider specialty on outcomes in ovarian cancer.
Gynecol Oncol. 2025;200:122-129.
PubMed Abstract available

LIGHTFOOT MDS, Sinnott JA, Meade CE, Barrington DA, et al
Enhancing predictive accuracy: Assessing the laparoscopic hysterectomy readmission score in a diverse endometrial cancer population.
Gynecol Oncol. 2025;200:105-111.
PubMed Abstract available

LEE KJ, Chokshi S, Joshi T, Cummings M, et al
Molecular comparison reveals distinct transcriptomic differences between uterine carcinosarcoma and papillary serous carcinoma distinguishable by DNA damage.
Gynecol Oncol. 2025;200:80-87.
PubMed Abstract available

MATULONIS UA, Vergote I, Moore KN, Martin LP, et al
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer.
Gynecol Oncol. 2025;200:96-104.
PubMed Abstract available

RAGLAND K, Pogue J, Simiele E, Simiele S, et al
The use of transrectal ultrasound to improve gynecologic interstitial applicator implantation.
Gynecol Oncol. 2025;200:88-95.
PubMed Abstract available

MCGAURAN M, Hyde S, Perera S, Lloyd M, et al
Perioperative outcomes after interval cytoreductive surgery and primary cytoreductive surgery for advanced epithelial ovarian cancer in Australia: A National Gynae-Oncology Registry (NGOR) study.
Gynecol Oncol. 2025;200:72-79.
PubMed Abstract available

CORR BR, Haggerty A, Gysler SM, Taylor S, et al
A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer.
Gynecol Oncol. 2025;200:58-67.
PubMed Abstract available

PESCE M, Tondo-Steele K, Stroup C, Straubhar A, et al
Persistent opioid use among gynecologic oncology patients after surgery.
Gynecol Oncol. 2025;200:68-71.
PubMed Abstract available

LAVEN P, Wenzel HHB, van der Aa MA, Lambrechts S, et al
Impact of lymph node dissection and adjuvant chemotherapy on survival of patients with early-stage ovarian cancer: Update of a national cohort study.
Gynecol Oncol. 2025;200:51-57.
PubMed Abstract available

CARUSO G, Ainio C, Fumagalli D, Reynolds EA, et al
Textbook oncologic outcome in endometrial cancer surgery: A quality measure to improve survival and address disparities.
Gynecol Oncol. 2025;200:33-43.
PubMed Abstract available

HE SY, Shen HW, Xu L, Zhao XH, et al
Corrigendum to "FOXM1 promotes tumor cell invasion and correlates with poor prognosis in early-stage cervical cancer" [Gynecologic Oncology 127 (2012) 601-610].
Gynecol Oncol. 2025 Jul 17:S0090-8258(25)00897.
PubMed

STOVER EH, Lee EK, Shapiro GI, Brugge JS, et al
The RAS-MEK-ERK pathway in low-grade serous ovarian cancer.
Gynecol Oncol. 2025;200:22-32.
PubMed Abstract available

KOIKE Y, Fujiwara A, Seki T, Kochi Y, et al
The detrimental impact of diverting ileostomy on renal function after tumor debulking surgery for advanced ovarian cancer.
Gynecol Oncol. 2025;200:14-21.
PubMed Abstract available

HUBINETTE M, Sundstrom-Poromaa I, Persson S, Elenis E, et al
Polycystic ovary syndrome and the risk of ovarian tumours.
Gynecol Oncol. 2025;200:1-7.
PubMed Abstract available

LEE SS, Secord AA, Friedman S, Hade EM, et al
Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therap
Gynecol Oncol. 2025;199:152-158.
PubMed Abstract available

BEKTAS O, Bektas K
Prognostic value of systemic inflammatory markers in predicting neoadjuvant platinum response and platinum resistance in advanced epithelial ovarian cancer: A peritoneal cancer index-based analysis.
Gynecol Oncol. 2025;199:147-151.
PubMed Abstract available

RODRIGUEZ VE, Ro A, Hoyt MA, Tanjasiri SP, et al
Racial/ethnic disparities in time from diagnosis to surgical treatment for type I and type II endometrial carcinomas.
Gynecol Oncol. 2025;199:139-146.
PubMed Abstract available

AINIO C, Rosanu M, Ribero L, Caruso G, et al
Surgical complexity and scope of procedures necessary after neoadjuvant chemotherapy for primary ovarian cancer.
Gynecol Oncol. 2025;199:133-138.
PubMed Abstract available

SU H, Shang X, Liu H, Tian M, et al
Low-dose lenvatinib plus toripalimab for patients with platinum-resistant recurrent ovarian cancer: preliminary results from a multicenter, phase II trial (NCT06241105).
Gynecol Oncol. 2025;199:124-132.
PubMed Abstract available

SILBERMAN JN, Benjamin A, Solk P, Matei D, et al
Fit4Surgery: A pilot randomized controlled trial to assess the feasibility of prehabilitation prior to debulking surgery for ovarian cancer.
Gynecol Oncol. 2025;199:116-123.
PubMed Abstract available

LIANG MI, Aviki EM, Agarwal R, Dholakia J, et al
What are we worth? An SGO analysis of compensation structures that measure and value work in academic gynecologic oncology practices.
Gynecol Oncol. 2025;199:108-115.
PubMed Abstract available

JOHNSON B, Milicia A, Hicks J, Hoskins E, et al
Delays, fragmentation, and desire for alternatives: A qualitative study of the patient experience through diagnosis and treatment of endometrial cancer.
Gynecol Oncol. 2025;199:103-107.
PubMed Abstract available

HARDESTY MM, Krivak TC, Wright GS, Hamilton E, et al
A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO.
Gynecol Oncol. 2025;199:96-102.
PubMed Abstract available

June 2025

RANDALL L, Xiang Y, Matsumoto T, Giannarelli D, et al
Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer.
Gynecol Oncol. 2025;199:88-95.
PubMed Abstract available

LINDEMANN K, Berton D, Sehouli J, Christensen RD, et al
NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer.
Gynecol Oncol. 2025;199:79-87.
PubMed Abstract available

DZYUBAK O, Glass K, Watts M, Tarafdar O, et al
Oncologic and fertility outcomes of progestin therapy for atypical hyperplasia and grade 1 cancer of the endometrium: Results of a specialized oncofertility program.
Gynecol Oncol. 2025;199:72-78.
PubMed Abstract available

GREENMAN M, Bellone S, Demirkiran C, Hartwich TMP, et al
Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma.
Gynecol Oncol. 2025;199:64-71.
PubMed Abstract available

WANG M, Dong T, Lucero M, Pan W, et al
Association between glucagon-like peptide-1 receptor agonists and ovarian cancer survival: A population-based cohort study.
Gynecol Oncol. 2025;199:57-63.
PubMed Abstract available

CHAN JK, Tewari K, Monk BJ, Herzog TJ, et al
Optimizing therapy for cervical cancers - Translating trial data into clinical decision-making.
Gynecol Oncol. 2025;199:47-50.
PubMed

KAHVECIOGLU A, Gultekin M, Yigit E, Sari SY, et al
Adjuvant radiotherapy outcomes and prognostic factors in FIGO 2023 stage IIC endometrial cancer: One sea, different depths.
Gynecol Oncol. 2025;199:40-46.
PubMed Abstract available

VARGIU V, Rosati A, Santullo F, Figa M, et al
REACT bowel REcovery after CyToreductive surgery for advanced ovarian cancer.
Gynecol Oncol. 2025;199:32-39.
PubMed Abstract available

LIU Y, Zhou Y, Zhou Z, Rao X, et al
GTN misdiagnosed as ectopic pregnancy: a 17-year retrospective cohort study.
Gynecol Oncol. 2025;199:27-31.
PubMed Abstract available

WEI TY, Wu CC, Hsu YT, Lin WH, et al
An exploratory analysis of driver gene alterations and their potential prognostic relevance in endometrial cancer with POLE exonuclease domain mutations.
Gynecol Oncol. 2025;199:17-26.
PubMed Abstract available

BIANCHI T, Grassi T, De Ponti E, Jaconi M, et al
Fertility sparing surgery in patients with advanced borderline ovarian tumors: Oncologic outcomes of a single-institution cohort.
Gynecol Oncol. 2025;199:10-16.
PubMed Abstract available

HUEPENBECKER SP, Iniesta MD, Munsell MF, Mandayam S, et al
No increase in chronic kidney disease after postoperative acute kidney injury in gynecologic oncologic ERAS surgery.
Gynecol Oncol. 2025;198:168-175.
PubMed Abstract available

DAMIAN FB, De Melo AC, Dal Molin GZ, Nogueira-Rodrigues A, et al
A phase II trial of palbociclib plus letrozole after progression on second-line chemotherapy for women with hormone receptor-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer (LACOG 1018).
Gynecol Oncol. 2025;198:161-167.
PubMed Abstract available

VINTZILEOS W, Beer H, Sunkara Y, Pruszynski J, et al
Prognostic indicators of recurrence and treatment-free interval in uterine carcinosarcoma.
Gynecol Oncol. 2025;198:154-160.
PubMed Abstract available

BOUAZZI M, Zheng G, Wang J, Baandrup L, et al
Use of statins and risk of ovarian cancer: evidence on effect modification by parity, menopause and endometriosis from nationwide nested case-control studies.
Gynecol Oncol. 2025;198:130-136.
PubMed Abstract available

MATSUO K, Friedman EL, Lee MW, Masjedi AD, et al
Cytology-negative, non-myoinvasive stage IC serous endometrial cancer: Assessment of adjuvant chemotherapy omission.
Gynecol Oncol. 2025;198:146-153.
PubMed Abstract available

NGUYEN JMV, Zigras T, Gayowsky A, Marcucci M, et al
Association of frailty with perioperative and survival outcomes in patients with gynecologic cancers: A population-based study.
Gynecol Oncol. 2025;198:137-145.
PubMed Abstract available

FU Z, Borho L, Taylor SE, Kelemen LE, et al
Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis.
Gynecol Oncol. 2025;198:112-129.
PubMed Abstract available

MELO V, Vanegas G, O'Riordan DL, Kuruvilla P, et al
A population health approach to assessing for and addressing palliative care needs in outpatients with advanced gynecologic malignancies.
Gynecol Oncol. 2025;198:104-111.
PubMed Abstract available

INIESTA MD, Ramirez PT, Munsell MF, Basabe S, et al
Integration of self-hypnosis in an enhanced recovery after surgery program in gynecologic oncology - A prospective randomized trial.
Gynecol Oncol. 2025;198:96-103.
PubMed Abstract available

RING KL, Mills AM, Howitt BE, Grisham RN, et al
Mesonephric-like adenocarcinoma of the female genital tract: Pathologic diagnosis, clinical outcomes, and novel therapeutics.
Gynecol Oncol. 2025;197:57-65.
PubMed Abstract available

KURNIT KC
The search for new therapeutic options for uterine carcinosarcoma.
Gynecol Oncol. 2025;197:A1-A2.
PubMed

May 2025

KISTENFEGER Q, Haight PJ, Levine M, Wang H, et al
The impact of antibiotics, proton pump inhibitors, H2-receptor antagonists, and steroids on survival in ovarian cancer patients receiving PARP inhibitor therapy.
Gynecol Oncol. 2025;198:90-95.
PubMed Abstract available

CHO WK, Park W, Kim SW, Lee KK, et al
Postoperative hypofractionated intensity-modulated radiation therapy in cervical cancer: prospective phase 2 trial (POHIM_RT study).
Gynecol Oncol. 2025;198:84-89.
PubMed Abstract available

PHAM ENB, van den Berg CB, Kokke NCCJ, van Marion R, et al
Molecular diversity in uterine carcinosarcoma: Beyond TP53.
Gynecol Oncol. 2025;198:75-83.
PubMed Abstract available

IIDA Y, Churchman M, Hollis RL, Taylor S, et al
Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinoma.
Gynecol Oncol. 2025;198:66-74.
PubMed Abstract available

LAM C, Zhou Q, Aghajanian C, Abu-Rustum NR, et al
Prognostic significance of estrogen receptor expression and estrogen signaling in endometrial carcinomas of no specific molecular profile: A comprehensive molecular and pathologic analysis.
Gynecol Oncol. 2025;198:59-65.
PubMed Abstract available

EHIMIAGHE E, Marjon N, Post MD, Corr BR, et al
The evolving role of HER2 in gynecologic oncology and clinical trial design: A gynecologic pathologist's perspective.
Gynecol Oncol. 2025;198:55-58.
PubMed

ACOSTA U, Bebia V, Torne A, Carreras-Dieguez N, et al
Topographic mapping of pelvic and aortic lymph node metastases in stage IIIC1r locally advanced cervical cancer: A retrospective study by the Spain-GOG group.
Gynecol Oncol. 2025;198:49-54.
PubMed Abstract available

NEWELL A, Andac-Jones E, Gonzalo M, Wright AA, et al
Patients with advanced ovarian cancer and their experiences and perceptions of sleep disturbance and fatigue across the treatment trajectory: A qualitative study.
Gynecol Oncol. 2025;198:42-48.
PubMed Abstract available

YANG W, Shen Y, Tian Y, Xiao X, et al
Evaluation of mutations detected in uterine exfoliated cells as a diagnostic tool for endometrial cancer.
Gynecol Oncol. 2025;198:33-41.
PubMed Abstract available

LEE JY, Boonyapipat S, Yuan G, Kim HS, et al
AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer.
Gynecol Oncol. 2025;198:25-32.
PubMed Abstract available

GU J, Zheng W, Li F, Luo C, et al
Redefining stage IVB cervical cancer: The unique prognosis of distant lymph node metastasis which is comparable to stage IIIC.
Gynecol Oncol. 2025;198:17-24.
PubMed Abstract available

BERG HF, Trovik J, Hjelmeland ME, Lien HE, et al
Pragmatic preoperative molecular classification of endometrial cancers; Replacing POLE sequencing with hormone receptor staining.
Gynecol Oncol. 2025;198:9-16.
PubMed Abstract available

LEE EK, Xiong N, Krasner C, Polak M, et al
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer.
Gynecol Oncol. 2025;198:1-8.
PubMed Abstract available

WAGAR MK, Reetz E, Huang D, Kao MJ, et al
Patterns of primary metastasis and recurrence in mismatch repair deficiency and p53 abnormal endometrial carcinoma.
Gynecol Oncol. 2025;197:171-178.
PubMed Abstract available

WAGGONER RM, Mahoney RP, Nathan D, Zell JA, et al
Assessing preventive gynecologic decisions in individuals with Lynch syndrome.
Gynecol Oncol. 2025;197:163-170.
PubMed Abstract available

BYRNE ME, Selenica P, Dessources K, Da Cruz Paula A, et al
Peritoneal washings analysis in endometrial cancer: Comparison of somatic mutation detection with panel sequencing and traditional cytology.
Gynecol Oncol. 2025;197:155-162.
PubMed Abstract available

XIAO Y, Pang J, Zhou Y, Lu J, et al
FRalpha expression in advanced endometrial carcinoma: Clinicopathological, molecular, and prognosis correlates.
Gynecol Oncol. 2025;197:146-154.
PubMed Abstract available

EVANS E, Dholakia J, Abraham J, Hinton A, et al
Whole-exome sequencing provides assessment of homologous recombination deficiency for identification of PARPi-responsive ovarian tumors.
Gynecol Oncol. 2025;197:139-145.
PubMed Abstract available

MOUFARRIJ S, Dopeso H, Brown DN, Green H, et al
TROP2 expression and therapeutic targeting in uterine carcinosarcoma.
Gynecol Oncol. 2025;197:129-138.
PubMed Abstract available

KARLSSON E, Vorobii O, Silins I, Sundstrom Poromaa I, et al
Splenectomy as an indicator for ovarian cancer spread and complete cytoreduction.
Gynecol Oncol. 2025;197:121-128.
PubMed Abstract available

KEVERLINE KJ, Hill B, Hom-Tedla M, Jacobs M, et al
Impact of mismatch repair (MMR) status on recurrence in high intermediate risk endometrial cancer.
Gynecol Oncol. 2025;197:116-120.
PubMed Abstract available

ETTORRE VM, Bellone S, Greenman M, McNamara B, et al
A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses.
Gynecol Oncol. 2025;197:110-115.
PubMed Abstract available

SUH-BURGMANN E, Hung YY, Finertie H, Zhong H, et al
Association of endometrial cancer epigenetic mismatch repair deficiency with clinicopathologic factors and survival in a large, diverse community-based cohort.
Gynecol Oncol. 2025;197:102-109.
PubMed Abstract available

THAKER PH, Richardson DL, Hagemann AR, Holloway RW, et al
OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer.
Gynecol Oncol. 2025 May 2:S0090-8258(25)00797.
PubMed Abstract available

ALIMENA S, Reid H, Bercow A, Feltmate C, et al
Trends in sentinel lymph node evaluation for vulvar melanoma in the United States from 2012 to 2018.
Gynecol Oncol. 2025;196:175-181.
PubMed Abstract available

CORNEL KMC, Mehta MP, Swift BE, Covens A, et al
The use of indocyanine green (ICG) for sentinel lymph node detection in vulvar cancer.
Gynecol Oncol. 2025;196:146-151.
PubMed Abstract available

STUEBS FA, Knoll A, Hartmann A, Matek C, et al
Trop2-expression in primary vulvar squamous cell carcinoma.
Gynecol Oncol. 2025;196:78-84.
PubMed Abstract available

April 2025

LOUKOVAARA M, Pasanen A, Butzow R
Molecular subgroup-specific prognostic value of semiquantitative lymphovascular space invasion in early-stage endometrioid endometrial cancer.
Gynecol Oncol. 2025;197:96-101.
PubMed Abstract available

BAE J, Kim U, Paik ES, Lim MC, et al
Oncologic outcomes of minimally invasive surgery vs. abdominal hysterectomy in patients with low-risk, early-stage cervical cancer: A retrospective analysis of KGOG 1028 data based on SHAPE trial eligibility criteria.
Gynecol Oncol. 2025;197:91-95.
PubMed Abstract available

JOHNSON CR, Aryasomayajula C, Francoeur AA, Stewart C, et al
Pathogenic germline variants among women with uterine cancer by ancestry: A commercial laboratory collaborative research registry study.
Gynecol Oncol. 2025;197:83-90.
PubMed Abstract available

POVEDA A, Lheureux S, Colombo N, Cibula D, et al
Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial.
Gynecol Oncol. 2025;197:74-82.
PubMed Abstract available

YOU B, Anderson C, Cecere SC, Carrot A, et al
Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial.
Gynecol Oncol. 2025;197:66-73.
PubMed Abstract available

FITZGERALD KJ, Konstantinopoulos P, Matulonis U, Liu J, et al
A phase I clinical trial of radiation therapy, durvalumab and tremelimumab in recurrent gynecologic cancer.
Gynecol Oncol. 2025;197:51-56.
PubMed Abstract available

LEON-CASTILLO A, Horeweg N, Peters EEM, Ter Haar N, et al
Pattern of recurrence of the molecular subgroups in stage I high-grade endometrial cancer.
Gynecol Oncol. 2025;197:43-50.
PubMed Abstract available

XIE J, Maguire FB, Hofer BM, Cooley JJP, et al
Disparities in hysterectomy-corrected endometrial cancer incidence trends by histologic subtype among racial/ethnic groups in California, 2012-2019.
Gynecol Oncol. 2025;197:34-42.
PubMed Abstract available

FRIEDMAN EL, Guo XM, Furey KB, Lee AJ, et al
Temporal trends of sentinel lymph node biopsy without lymphadenectomy at cervical cancer surgery.
Gynecol Oncol. 2025;196:182-191.
PubMed Abstract available

GRCEVICH L, Chuzhyk O, Giannini A, McGree ME, et al
Safety and feasibility of same day discharge for robotic hysterectomy and staging for endometrial cancer.
Gynecol Oncol. 2025;197:19-24.
PubMed Abstract available

WILKE RN, Wu CF, Kanbergs A, Bercow AS, et al
Disparities in facility-level adoption of minimally invasive interval debulking surgery for advanced ovarian cancer.
Gynecol Oncol. 2025;197:11-18.
PubMed Abstract available

RIOS-DORIA E, Parker EU, Kohrn BF, Pike M, et al
TP53 somatic evolution in the normal endometrium of Black and White individuals.
Gynecol Oncol. 2025;197:1-10.
PubMed Abstract available

MORRIS DH, Kosmacki A, Tolby L, Marx C, et al
Integration of a lifestyle modification intervention for women with overweight and obesity in a gynecologic oncology practice.
Gynecol Oncol. 2025;196:168-174.
PubMed Abstract available

BORCINOVA M, Kohler C, Nemejcova K, Zapardiel I, et al
Preoperative tumour size assessment in patients with early-stage cervical cancer: Final results of the SENTIX study.
Gynecol Oncol. 2025;196:160-167.
PubMed Abstract available

RAIMONDO D, Raffone A, Maletta M, Restaino S, et al
Hysterectomy or not for borderline ovarian tumor in menopause?
Gynecol Oncol. 2025;196:152-159.
PubMed Abstract available

ZELISSE HS, Snijders MLH, Groenendijk FH, Halfwerk JBG, et al
The prognostic potential of molecular subtypes including estrogen receptor status in endometrioid ovarian cancer.
Gynecol Oncol. 2025;196:137-145.
PubMed Abstract available

METTALA T, Joutsiniemi T, Huvila J, Hietanen S, et al
Genetic predictors of unexpected recurrence in low-risk endometrial cancer: A comprehensive genomic analysis reveals FGFR2 as a risk factor and a rare fatal POLE-mutated recurrence.
Gynecol Oncol. 2025;196:129-136.
PubMed Abstract available

HABLASE R, Steinke J, Aslam A, Jose R, et al
Anastomotic leakage in colorectal and ovarian cancer resections: A comparative cohort study.
Gynecol Oncol. 2025;196:121-128.
PubMed Abstract available

GONZALEZ-BOSQUET J, Shahi M, Yadav S, Kanwar N, et al
ECPPF stratification identifies occult high-risk subgroups in stage I, grade 1 or 2,
Gynecol Oncol. 2025;196:113-120.
PubMed Abstract available

COSGROVE CM, Suarez AA, Haight PJ, Villacres A, et al
Exploring endometrial cancer risk stratification by copy number assessment.
Gynecol Oncol. 2025;196:99-106.
PubMed Abstract available

KAHN RM, Murphy K, Patel T, Yeoshoua E, et al
Three-dimensional volumetric rendering on augmented reality headsets for ovarian cancer cytoreduction planning: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol. 2025;196:107-112.
PubMed Abstract available

VARGIU V, Santullo F, Scambia G, Naldini A, et al
STOMA study SToma-leak ratio in advanced ovarian cancer surgery: Results of a restrictive policy on the use of protective stoMAs.
Gynecol Oncol. 2025;196:92-98.
PubMed Abstract available

BUJNAK AC, Greenberg D, Chang J, Tseng J, et al
Adjuvant treatment in stage I clear cell endometrial carcinoma: A population-based study of survival outcomes.
Gynecol Oncol. 2025;196:85-91.
PubMed Abstract available

WOLF B, Trantaki DS, Horn LC, Aktas B, et al
Preoperative conization in cervical cancer patients undergoing open abdominal radical hysterectomy: Results from a propensity-score matched study.
Gynecol Oncol. 2025;196:69-77.
PubMed Abstract available

WESTRICK AC, Bailey Z, Schlumbrecht M
Influence of residential segregation and health provider density on advanced stage endometrial cancer diagnoses.
Gynecol Oncol. 2025;196:62-68.
PubMed Abstract available

HAGHIGHAT R, Ozarowski AL, Liu YL, Frey MK, et al
MUTYH: Possibly another important gene in ovarian cancer?
Gynecol Oncol. 2025;196:59-61.
PubMed

CIOFFI R, Fruscio R, Sabetta G, Bergamini A, et al
Consolidation courses in low-risk gestational trophoblastic neoplasia and relapse rate: A MITO-9 retrospective study.
Gynecol Oncol. 2025;196:54-58.
PubMed Abstract available

CHAM S, Kumar A, Walter LC, Lichtman S, et al
Understanding frailty and the role of patient-centered care for older adults with gynecologic cancer.
Gynecol Oncol. 2025;196:42-53.
PubMed Abstract available

TA QD, Do C, Sharma K, Sorooshian HZ, et al
Reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer.
Gynecol Oncol. 2025;196:36-41.
PubMed Abstract available

LEATH CA 3RD, Deng W, Mell LK, Richardson DL, et al
Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.
Gynecol Oncol. 2025;195:122-133.
PubMed Abstract available

BRINK GJ, Groeneweg JW, van der Ploeg P, Jonges GN, et al
Signal transduction pathway activity in adult-type granulosa cell tumor samples.
Gynecol Oncol. 2025;195:6-11.
PubMed Abstract available

PODDER V, Slomovitz BM
Rethinking metformin in advanced endometrial cancer: Scientific humility, translational challenges, and the urgency for equity.
Gynecol Oncol. 2025;195:A1-A2.
PubMed

March 2025

LORUSSO D, Oaknin A, Borges GS, Damian F, et al
Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial.
Gynecol Oncol. 2025;196:28-35.
PubMed Abstract available

XIE H, Sun L, Yao S, Tian X, et al
Therapeutically targeting endometrial cancer in preclinical models by ICAM1 antibody-drug conjugates.
Gynecol Oncol. 2025;196:16-27.
PubMed Abstract available

KIM J, Jang J, Lim MC, Kim MH, et al
Which factors predict the effectiveness of adjuvant treatment in patients with non-high-risk early-stage cervical cancer? Ancillary analysis of KGOG-1028.
Gynecol Oncol. 2025;196:10-15.
PubMed Abstract available

MATULONIS UA, Herrstedt J, Oza A, Mahner S, et al
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety.
Gynecol Oncol. 2025;195:192-199.
PubMed Abstract available

BUJNAK AC, Solaru SA, Tewari K
Clinical applications of antibody drug conjugates for gynecologic malignancies: Review of available medicines and emerging therapeutics.
Gynecol Oncol. 2025;195:180-191.
PubMed Abstract available

ETHIER JL, Shephard C, Granados DP, Dutta N, et al
Comparative efficacy and safety of low-dose versus high-dose bevacizumab in ovarian cancer: An indirect treatment comparison.
Gynecol Oncol. 2025;196:1-9.
PubMed Abstract available

JOHANNET P, Flint M, Chui MH, Konner J, et al
Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate.
Gynecol Oncol. 2025;195:173-179.
PubMed Abstract available

LI Y, Wu M, Liu Q, Huang C, et al
Development and validation of an ovarian cancer risk assessment tool for first-degree relatives of patients in the Chinese population.
Gynecol Oncol. 2025;195:165-172.
PubMed Abstract available

LEE EK, Kolin DL, Matulonis UA, Erickson BK, et al
Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers.
Gynecol Oncol. 2025;195:152-164.
PubMed Abstract available

DEMARI JA, Glassman D, Smith S, Darby JP, et al
Endometrial cancer somatic testing practice patterns among gynecologic oncologists.
Gynecol Oncol. 2025;195:149-151.
PubMed

SULLIVAN MW, Chui MH, Selenica P, Long Roche K, et al
Anaplastic carcinoma of the ovary: A single-institution experience and molecular analysis.
Gynecol Oncol. 2025;195:144-148.
PubMed Abstract available

DE BONDT D, Naslazi E, Jansen E, Kupets R, et al
Validating the predicted impact of HPV vaccination on HPV prevalence, cervical lesions, and cervical cancer: A systematic review of population level data and modelling studies.
Gynecol Oncol. 2025;195:134-143.
PubMed Abstract available

CARUSO G, Kumar A, Langstraat CL, McGree ME, et al
Racial/ethnic, socioeconomic, and healthcare access disparities in achieving textbook oncologic outcome in advanced ovarian cancer.
Gynecol Oncol. 2025;195:106-114.
PubMed Abstract available

SALINARO J, Singh K, Sands N, Gill V, et al
Distribution and concordance of HER2 scores in endometrial and ovarian cancer.
Gynecol Oncol. 2025;195:115-121.
PubMed Abstract available

ENGH A, Rueegg CS, Bjerre Trent PK, Opheim LO, et al
Physical activity and lower extremity lymphedema among endometrial cancer survivors: A population-based cross-sectional study.
Gynecol Oncol. 2025;195:82-88.
PubMed Abstract available

LINDEMANN K, Siegenthaler F, Lande KT, Casas-Arozamena C, et al
Prognostic value of assessing ctDNA in patients with endometrial carcinoma - an international multicenter study.
Gynecol Oncol. 2025;195:98-105.
PubMed Abstract available

ZAMMARRELLI WA 3RD, Nandakumar S, Kertowidjojo E, Nguyen B, et al
The genomic landscape of distant metastatic endometrial cancer.
Gynecol Oncol. 2025;195:89-97.
PubMed Abstract available

TYAN K, Liu KX, Smart AC, Feltmate CM, et al
Role of adjuvant radiotherapy modality on clinical outcomes for early-stage uterine carcinosarcoma.
Gynecol Oncol. 2025;195:75-81.
PubMed Abstract available

CARTER J, Huang HQ, Monk BJ, Kim YB, et al
Evaluation of physical function and quality of life before and after nonradical surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278).
Gynecol Oncol. 2025;195:50-58.
PubMed Abstract available

BAE-JUMP VL, Sill MW, Gehrig PA, Merker JD, et al
A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study.
Gynecol Oncol. 2025;195:66-74.
PubMed Abstract available

COVENS A, Huang HQ, Monk BJ, Kim YB, et al
Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278).
Gynecol Oncol. 2025;195:59-65.
PubMed Abstract available

LA TORRE F, Hurni Y, Farsi E, Nardi E, et al
Adenomyosis associated with endometrial cancer: Possible correlation with pathological, immunohistochemical and molecular characteristics.
Gynecol Oncol. 2025;195:45-49.
PubMed Abstract available

LI X, Wang Z, Man X, Dai X, et al
Research advances CRISPR gene editing technology generated models in the study of epithelial ovarian carcinoma.
Gynecol Oncol. 2025;195:34-44.
PubMed Abstract available

HICKS A, Borho L, Elishaev E, Berger J, et al
All-cause mortality and neighborhood social vulnerability among women with ovarian cancer.
Gynecol Oncol. 2025;195:26-33.
PubMed Abstract available

MARCHETTI C, Ergasti R, Capomacchia FM, Giannarelli D, et al
Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery.
Gynecol Oncol. 2025;195:16-25.
PubMed Abstract available

FUCA G, Dell'Acqua C, Peruffo B, Lalli G, et al
WRN dependency in dMMR/MSI-H endometrial cancer: Clinical perspectives of a novel synthetic lethality strategy.
Gynecol Oncol. 2025;195:12-15.
PubMed

DINKINS KG, Lee GM, Arend RC, Leath CA 3rd, et al
Trends in FDA approvals of gynecologic oncology therapeutics from 2019 to 2024.
Gynecol Oncol. 2025;194:153-158.
PubMed Abstract available

HERZOG TJ, Liao JB, Finkelstein K, Willmott L, et al
An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044).
Gynecol Oncol. 2025;194:145-152.
PubMed Abstract available

WENZEL L, McKinney C, Jensen S, Peipert D, et al
Ensuring relevance and equity in patient reported outcomes (PROs) in endometrial cancer: The SGO promote study (Patient Reported Outcomes Measurement Opportunities Through Equity).
Gynecol Oncol. 2025;194:137-144.
PubMed Abstract available

VELASQUEZ J, Mohammed-Norgan M, Scheiber A, Chalif J, et al
Cross-language insights: Comparing Spanish and English-language cervical cancer content on TikTok.
Gynecol Oncol. 2025;194:131-136.
PubMed Abstract available

LI J, Welte T, Calzoncinth K, Vuttaradhi VK, et al
An inducible FOXL2-dependent mouse model of ovarian adult type granulosa cell tumor.
Gynecol Oncol. 2025;194:125-130.
PubMed Abstract available

DEBBICHE I, Wang CC, Gomez-Roas M, Foley OW, et al
Rest assured: High sleep efficiency reduces postoperative complications and opioid prescriptions in patients undergoing surgeries with gynecologic oncologists.
Gynecol Oncol. 2025;194:119-124.
PubMed Abstract available

VAN VELZEN AF, Tulling AJ, van Poelgeest MIE, Bosse T, et al
Predicting lymph node metastases in three different vulvar squamous cell carcinoma subgroups.
Gynecol Oncol. 2025;194:86-90.
PubMed Abstract available

ZANNONI GF, Angelico G, Spadola S, Bragantini E, et al
Chemotherapy Response Score (CRS): A comprehensive review of its prognostic and predictive value in High-Grade Serous Carcinoma (HGSC).
Gynecol Oncol. 2025;194:1-10.
PubMed Abstract available

ESKANDER RN
Implications of the platinum-free interval in endometrial cancer: A legacy worth leaving behind?
Gynecol Oncol. 2025;194:A3-A4.
PubMed

February 2025

WALKER AR, Leite S, Chen YS, Huepenbecker SP, et al
Sentinel lymph node biopsy at the time of hysterectomy for early-stage cervical cancer: A cost-effectiveness analysis.
Gynecol Oncol. 2025;195:1-5.
PubMed Abstract available

ASARE A, Previs RA, Spinosa D, Fellman B, et al
Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.
Gynecol Oncol. 2025;194:112-118.
PubMed Abstract available

HAIGHT PJ, Sanchez M, Thomas SM, Smitherman C, et al
Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study.
Gynecol Oncol. 2025;194:98-104.
PubMed Abstract available

NOLIN AC, Atkins SL, Myers ER, Wentzensen N, et al
Ultrasound-based versus immediate biopsy-based management of postmenopausal bleeding in non-Hispanic Black and non-Hispanic White individuals.
Gynecol Oncol. 2025;194:105-111.
PubMed Abstract available

MACDUFFIE E, Kernell C, George J, Bvochora-Nsingo M, et al
Efficacy of induction chemotherapy during the COVID-19 pandemic for treatment of locally advanced cervical cancer in Botswana.
Gynecol Oncol. 2025;194:91-97.
PubMed Abstract available

HAIGHT P, Bilbe C, Riedinger C, Backes F, et al
Defining "enlarged" sentinel lymph nodes in the setting of endometrial cancer: What is the size cut-off?
Gynecol Oncol. 2025;194:80-85.
PubMed Abstract available

ALVERO AB, Wu S, Farrell A, Kim S, et al
Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis.
Gynecol Oncol. 2025;194:71-79.
PubMed Abstract available

SUN H, Huo X, Bi X, Cao D, et al
Exosome transmit the ability of migration and invasion in heterogeneous ovarian cancer cells by regulating autophagy via targeting hsa-miR-328.
Gynecol Oncol. 2025;194:60-70.
PubMed Abstract available

MATSUO K, Agarwal J, Chen L, Furey KB, et al
Histology-specific prognostic significance of isolated tumor cells, micrometastases, and macrometastases in endometrial cancer.
Gynecol Oncol. 2025;194:51-59.
PubMed Abstract available

TUBRIDY EA, Campbell A, Mulugeta-Gordon L, Andriani L, et al
Impact of telehealth legislation on gynecologic oncology services: Policy updates.
Gynecol Oncol. 2025;194:48-50.
PubMed

GAILLARD S, Verma N, Berg M, Harrison J, et al
A clinical study of tremelimumab, alone or in combination with olaparib, for recurrent epithelial ovarian cancer.
Gynecol Oncol. 2025;194:41-47.
PubMed Abstract available

CORTES-SALGADO A, Moreno-Moreno E, Carretero-Barrio I, Caniego-Casas T, et al
HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study.
Gynecol Oncol. 2025;194:33-40.
PubMed Abstract available

KIM J, Park SY, Kim JH, Lee SW, et al
Real-world efficacy and toxicity of olaparib maintenance therapy in Korean ovarian cancer patients with an exploratory analysis of BRCA mutations.
Gynecol Oncol. 2025;194:25-32.
PubMed Abstract available

ROMERO IL, Lengyel E, Wahner Hendrickson AE, Rodriguez GC, et al
Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial.
Gynecol Oncol. 2025;194:18-24.
PubMed Abstract available

VALENZA C, Mongillo M, Visconti MV, Katrini J, et al
Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study.
Gynecol Oncol. 2025;194:11-17.
PubMed Abstract available

CORVIGNO S, Fernebro J, Karlsson JS, Mezheieusky A, et al
High prevalence of FAP+ cancer-associated fibroblasts predicts poor outcome in patients with high-grade serous ovarian cancer with high CD8 T-cell density.
Gynecol Oncol. 2025;193:148-155.
PubMed Abstract available

STUEBS FA, Knoll A, Hartmann A, Leikauf LS, et al
PD-L1-Expression in primary and recurrent vulvar squamous cell cancer.
Gynecol Oncol. 2025;193:98-104.
PubMed Abstract available

HOROWITZ NS, St Laurent JD, Berkowitz RS
Prevention of gestational trophoblastic neoplasia with actinomycin -D at the time of evacuation: A matter of routine practice or reserve for special circumstances?
Gynecol Oncol. 2025;193:A1-A2.
PubMed

January 2025

MAKI PM, Rubin LH, Krejany EO, Brand A, et al
What happens after menopause? (WHAM): A prospective controlled study of cognition 24 months after premenopausal risk-reducing salpingo-oophorectomy.
Gynecol Oncol. 2025;193:141-147.
PubMed Abstract available

KIM YJ, Lee J, Park S, Kim YM, et al
The value of magnetic resonance imaging in predicting vesicovaginal fistula in cervical cancer with bladder invasion treated with definitive chemoradiotherapy.
Gynecol Oncol. 2025;193:136-140.
PubMed Abstract available

CLEMENTS A, Enserro D, Strickland KC, Previs R, et al
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.
Gynecol Oncol. 2025;193:119-129.
PubMed Abstract available

O'MALLEY DM, Bariani GM, Cassier PA, Marabelle A, et al
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results.
Gynecol Oncol. 2025;193:130-135.
PubMed Abstract available

TOBONI MD, Dinkins K, Wu S, Mattox T, et al
Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma.
Gynecol Oncol. 2025;193:89-97.
PubMed Abstract available

SCHAAFSMA M, Schuurman TN, Siebers AG, Bekkers RLM, et al
Cost-effectiveness of an additional hysterectomy after initially conservative treatment for cervical adenocarcinoma in situ.
Gynecol Oncol. 2025;193:113-118.
PubMed Abstract available

UBERTI EMH, de Freitas Medeiros LR, Cardoso RB, Muller KP, et al
Primary prevention of post-molar gestational trophoblastic neoplasia in high-risk complete hydatidiform mole: A single-dose prophylactic actinomycin D, associated with uterine evacuation - a long retrospective cohort study.
Gynecol Oncol. 2025;193:105-112.
PubMed Abstract available

DE VITIS LA, Reyes-Baez FE, Schivardi G, Shahi M, et al
Cervical stromal invasion and molecular characterization in stage II-IV endometrial cancers.
Gynecol Oncol. 2025;193:81-88.
PubMed Abstract available

WANG H, Zhu J, Zou D, Rao Q, et al
Multicenter study of ovarian cancer score for diagnosing ovarian cancer.
Gynecol Oncol. 2025;193:58-64.
PubMed Abstract available

AHMED J, Stephen B, Khawaja MR, Yang Y, et al
A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer.
Gynecol Oncol. 2025;193:73-80.
PubMed Abstract available

MIRZA HB, Hunt A, Ennis DP, McDermott J, et al
Spatial transcriptomic analysis reveals significant differences in tumor microenvironment in HPV-dependent and HPV-independent vulvar squamous cell carcinoma.
Gynecol Oncol. 2025;193:65-72.
PubMed Abstract available

LEIJTENS L, Piek J, Verrijssen AS, Rijkaart D, et al
Thromboprophylaxis in patients with locally advanced cervical cancer treated with chemoradiation and brachytherapy.
Gynecol Oncol. 2025;193:41-48.
PubMed Abstract available

RICCIUTI J, Liu Q, Khan ANMNH, Joseph JM, et al
Prognostic significance of serum complement activation, neutrophil extracellular traps and extracellular DNA in newly diagnosed epithelial ovarian cancer.
Gynecol Oncol. 2025;193:49-57.
PubMed Abstract available

BOGANI G, Moore KN, Ray-Coquard I, Lorusso D, et al
Incorporating immune checkpoint inhibitors in epithelial ovarian cancer.
Gynecol Oncol. 2025;193:30-40.
PubMed Abstract available

WALKER AR, Leite S, Taylor N, Graul A, et al
Lymph node assessment at the time of robotic hysterectomy for endometrial intraepithelial neoplasia: A cost-effectiveness analysis.
Gynecol Oncol. 2025;193:24-29.
PubMed Abstract available

SIEGENTHALER F, Imboden S, Buchi C, Christe L, et al
Added prognostic value of sentinel lymph node mapping in endometrial cancer to molecular subgroups.
Gynecol Oncol. 2025;193:12-19.
PubMed Abstract available

VOSS FO, Fons G, Bruggink AH, Wenzel HHB, et al
Prevalence and impact of vulvar lesions diagnosed prior to vulvar squamous cell carcinoma: A population-based cohort study.
Gynecol Oncol. 2025;192:163-170.
PubMed Abstract available

MARINO G, Marchetta L, Negri S, Testa F, et al
Oncologic and fertility outcomes in patients with juvenile granulosa cell tumor - a retrospective single centre analysis.
Gynecol Oncol. 2025;192:89-93.
PubMed Abstract available

December 2024

NEILSON A, Jamieson A, Chiu D, Leung S, et al
Serum CA125 levels in the context of ProMisE molecular classification provides pre-operative prognostic information that can direct endometrial cancer management.
Gynecol Oncol. 2024;193:1-11.
PubMed Abstract available

MADDY BP, Tischer KM, McGree ME, Fought AJ, et al
Implementation of enhanced recovery protocol did not increase rates of acute kidney injury in open gynecologic oncology surgery: A single-institution experience.
Gynecol Oncol. 2024;192:181-188.
PubMed Abstract available

VOS JAM, Vos MC, van Lonkhuijzen LRCW, van de Poll-Franse LV, et al
Less is more: The benefits of reduced follow-up in gynecologic cancers.
Gynecol Oncol. 2024;192:178-180.
PubMed

LIU YL, Praiss AM, Chiang S, Devereaux K, et al
Gestational trophoblastic neoplasm: Patient outcomes and clinical pearls from a multidisciplinary referral center.
Gynecol Oncol. 2024;192:171-177.
PubMed Abstract available

KONUMA M, Ikeda T, Mitoma T, Shirakawa S, et al
Effectiveness of exercise therapy on chemotherapy-induced peripheral neuropathy in patients with ovarian cancer: A scoping review.
Gynecol Oncol. 2024;192:155-162.
PubMed Abstract available

AZAIS H, Brochard C, Taly V, Benoit L, et al
Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial.
Gynecol Oncol. 2024;192:145-154.
PubMed Abstract available

NGUYEN T, Yi Y, Morron S, Brittain D, et al
Living in a food desert in Louisiana and its effects on gynecologic cancer outcomes.
Gynecol Oncol. 2024;192:137-144.
PubMed Abstract available

MIRZA MR, Bjorge L, Marme F, Christensen RD, et al
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.
Gynecol Oncol. 2024;192:128-136.
PubMed Abstract available

GRAVES S, Sullivan MW, Adkoli A, Zhou Q, et al
Association between genomic instability score and progression-free/overall survival in patients with newly diagnosed non-BRCA1/2 ovarian cancer.
Gynecol Oncol. 2024;192:120-127.
PubMed Abstract available

CASTELLANO T, Lara OD, McCormick C, Chase D, et al
Clinical trial screening in gynecologic oncology: Defining the need and identifying best practices.
Gynecol Oncol. 2024;192:111-119.
PubMed Abstract available

PREVIS RA, Strickland KC, Wallen Z, Ko H, et al
Analysis of real world FRalpha testing in ovarian, fallopian tube, and primary peritoneal cancers.
Gynecol Oncol. 2024;192:102-110.
PubMed Abstract available

COLSON-FEARON D, Viswanathan AN
Trends in brachytherapy in utilization for vaginal cancer in the United States from 2004 to 2021.
Gynecol Oncol. 2024;191:228-232.
PubMed Abstract available

MOUFARRIJ S, Dagher C, Filippova OT, Zhou Q, et al
Five-year quality-of-life assessment by urinary diversion type after pelvic Exenterations.
Gynecol Oncol. 2024;191:212-218.
PubMed Abstract available

FEDERICO A, Lancellotta V, Fragomeni SM, Macchia G, et al
Surgery after upfront chemoradiation in locally advanced squamous cell vulvar cancer: Analysis of postoperative outcomes and survival.
Gynecol Oncol. 2024;191:106-113.
PubMed Abstract available

WONG TY, Adzibolosu NK, Mattei LH, Speak AC, et al
Disparities in contemporary human papilloma virus vaccination uptake among adult women living in the United States: An All of Us Research Program study.
Gynecol Oncol. 2024;191:100-105.
PubMed Abstract available

THAYER EG, Manning-Geist BL
Following the folate receptor: Expanding targeted treatment options in low grade serous ovarian carcinoma.
Gynecol Oncol. 2024;191:A1-A2.
PubMed

November 2024

SHU T, Liang Y, Zhang S, Sun T, et al
The prognostic value of tumor-informed minimal residual disease detection using circulating tumor DNA in first-line treatment of ovarian cancer.
Gynecol Oncol. 2024;192:94-101.
PubMed Abstract available

BORHO L, Elishaev E, Bao R, O'Brien E, et al
Association of neighborhood social vulnerability with ovarian cancer survival.
Gynecol Oncol. 2024;192:32-39.
PubMed Abstract available

KLEPPE A, Lindemann K, Kildal W, Tobin KAR, et al
Prognostic and therapeutic implication of molecular classification including L1CAM expression in high-risk endometrial cancer.
Gynecol Oncol. 2024;192:80-88.
PubMed Abstract available

CLASSEN CC, Chivers ML, Brotto LA, Barbera L, et al
A randomized controlled trial of an online support group addressing psychosexual distress among women treated for gynecologic cancer.
Gynecol Oncol. 2024;192:73-79.
PubMed Abstract available

SONAVANE M, Hedlich-Dwyer J, Dal Zotto VL, Tang M, et al
Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer.
Gynecol Oncol. 2024;192:65-72.
PubMed Abstract available

KHADRAOUI W, Sinnott JA, Meade CE, Plascak J, et al
Clinical trial enrollment during first course of gynecologic cancer treatment and survival.
Gynecol Oncol. 2024;192:59-64.
PubMed Abstract available

MULUGETA-GORDON L, Smith AJB
Insurance coverage and access to gynecologic oncology: Where are we are now.
Gynecol Oncol. 2024;192:56-58.
PubMed Abstract available

FRANCIS KE, Simon S, Gebski V, Joly F, et al
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer.
Gynecol Oncol. 2024;192:50-55.
PubMed Abstract available

POWELL MA, Cibula D, O'Malley DM, Boere I, et al
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Gynecol Oncol. 2024;192:40-49.
PubMed Abstract available

COLEMAN RL, Lubinga SJ, Shen Q, Walder L, et al
Cost-effectiveness of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a US payer perspective.
Gynecol Oncol. 2024;192:24-31.
PubMed Abstract available

DE JAEGHERE EA, Hamerlinck H, Tuyaerts S, Lippens L, et al
Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trial.
Gynecol Oncol. 2024;191:275-286.
PubMed Abstract available

VREDE SW, Van Weelden WJ, Bulten J, Gilks CB, et al
Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer.
Gynecol Oncol. 2024;192:15-23.
PubMed Abstract available

MOUFARRIJ S, Lakhman Y, Aghajanian C, Abu-Rustum NR, et al
Evolutionary pathways in early-stage, non-myoinvasive endometrioid endometrial cancers of no specific molecular profile.
Gynecol Oncol. 2024;192:8-14.
PubMed Abstract available

HICKEY M, Nguyen TL, Krejany EO, Domchek SM, et al
What happens after menopause? (WHAM): Impact of risk-reducing salpingo-oophorectomy on depressive and anxiety symptoms at 24 months.
Gynecol Oncol. 2024;192:1-7.
PubMed Abstract available

KILOWSKI KA, Dietrich MF, Xiu J, Baca Y, et al
KRAS mutations in endometrial cancers: Possible prognostic and treatment implications.
Gynecol Oncol. 2024;191:299-306.
PubMed Abstract available

LEE AW, Poynor V, Siddiqui S
Disparities in ovarian cancer survival among ethnic Asian American populations, 2006-2020.
Gynecol Oncol. 2024;191:292-298.
PubMed Abstract available

BOITANO TKL, Blank SV, Havrilesky LJ, Huh WK, et al
Too much of a good thing? Projecting the need for gynecologic oncologists over the next 20 years.
Gynecol Oncol. 2024;191:287-291.
PubMed Abstract available

JAIN D, Zaeim F, Wahidi M, Smith WJ, et al
Cervical squamous cell carcinoma outcomes across continents: A retrospective study.
Gynecol Oncol. 2024;190:272-282.
PubMed Abstract available

PROPPE L, Jaeger A, Goy Y, Petersen C, et al
Systematic review - Adjuvant radiotherapy of the vulva in primary vulvar cancer.
Gynecol Oncol. 2024;190:264-271.
PubMed Abstract available

CHOI YK, Lee JH, Kim YS, Wee CW, et al
Mid-treatment MRI-based tumor response assessment for tumor recurrence and patient survival in locally advanced adenocarcinoma of the cervix: A retrospective multicenter study of KROG 23-03.
Gynecol Oncol. 2024;190:222-229.
PubMed Abstract available

SHIBATA M, Yoshida K, Yokoi A, Suzuki H, et al
Elucidation of the role of XBP1 in the progression of complete hydatidiform mole to invasive mole through RNA-seq.
Gynecol Oncol. 2024;190:189-199.
PubMed Abstract available

NONZEE NJ, Thiel de Bocanegra H, Navarro S, Bastani R, et al
Impact of management guidelines for abnormal cervical cytology on colposcopy procedure rates among young women.
Gynecol Oncol. 2024;190:160-166.
PubMed Abstract available

HEUS C, Stelten S, Kenter GG, Buffart LM, et al
Body composition and peri- and postoperative complications in patients with gynaecological malignancies: A systematic review.
Gynecol Oncol. 2024;190:131-138.
PubMed Abstract available

WEBBER JW, Wollborn L, Mishra S, Vitonis AF, et al
Serum miRNA improves the accuracy of a multivariate index assay for triage of an adnexal mass.
Gynecol Oncol. 2024;190:124-130.
PubMed Abstract available

METCALF CA, Page CE, Stocker BOS, Johnson RL, et al
Treating new-onset cognitive complaints after risk-reducing salpingo-oophorectomy: A randomized controlled crossover trial of lisdexamfetamine.
Gynecol Oncol. 2024;190:62-69.
PubMed Abstract available

MERTEN R, Strnad V, Karius A, Lotter M, et al
Brachytherapy in vaginal cancer for organ preservation: Clinical outcome and safety from a single center experience.
Gynecol Oncol. 2024;190:35-41.
PubMed Abstract available

TEE XR, Hazard E, Latorre-Esteves E, Kohrn BF, et al
Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1 germline mutations.
Gynecol Oncol. 2024;190:18-27.
PubMed Abstract available

BROWN J
Hormonal maintenance therapy for advance low grade serous ovarian carcinoma appears to be of benefit - That's a relief!
Gynecol Oncol. 2024;190:A1-A2.
PubMed

October 2024

VER HOEVE ES, Rumble ME, Gorzelitz JS, Rose SL, et al
Biobehavioral predictors of mood, pain, fatigue, and insomnia in endometrial cancer survivors.
Gynecol Oncol. 2024;191:265-274.
PubMed Abstract available

HUNSBERGER KS, Tewari KS, Monk BJ, Chase DM, et al
Standard of care treatment for stage IVB cervical cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2024;191:259-264.
PubMed Abstract available

MOORE KN, Lorusso D, Oaknin A, Oza A, et al
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.
Gynecol Oncol. 2024;191:249-258.
PubMed Abstract available

PENG S, Zheng Y, Liu J, Chen S, et al
Molecular classification in fertility-sparing treatment of early-stage endometrial cancer: A potential tool for optimizing patient selection.
Gynecol Oncol. 2024;191:240-248.
PubMed Abstract available

GARCIA-DONAS J, Redondo A, Santaballa A, Garrigos L, et al
Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01).
Gynecol Oncol. 2024;191:233-239.
PubMed Abstract available

NAGASE Y, Matsuo K, Nakao Y, Hisa T, et al
Adjuvant therapy de-escalation for stage I uterine leiomyosarcoma: A systematic review and meta-analysis.
Gynecol Oncol. 2024;191:219-227.
PubMed Abstract available

LI G, Li X, Yin R, Feng M, et al
Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer.
Gynecol Oncol. 2024;191:165-171.
PubMed Abstract available

HICKEY M, Trainer AH, Krejany EO, Brand A, et al
What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 24 months after premenopausal risk-reducing salpingo-oophorectomy (RRSO).
Gynecol Oncol. 2024;191:201-211.
PubMed Abstract available

HAIGHT PJ, Lammers S, Kistenfeger Q, Leipold C, et al
Cold ischemia time and formalin fixation time in endometrial cancer: Should breast cancer guidelines for preanalytical variables be applied to hysterectomy specimens?
Gynecol Oncol. 2024;191:194-200.
PubMed Abstract available

YONEMORI K, Boni V, Min KG, Meniawy TM, et al
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study.
Gynecol Oncol. 2024;191:172-181.
PubMed Abstract available

ELAYAPILLAI SP, Dogra S, Lausen J, Parker M, et al
ATR inhibition increases reliance on PARP-mediated DNA repair revealing an improved therapeutic strategy for cervical cancer.
Gynecol Oncol. 2024;191:182-193.
PubMed Abstract available

PLINSINGA ML, Rye S, Jones T, Vagenas D, et al
Mild symptoms matter: Results from a prospective, longitudinal study on the relationship between symptoms, lymphedema and health-related outcomes post-gynecological cancer.
Gynecol Oncol. 2024;191:158-164.
PubMed Abstract available

PERRONE E, Capasso I, Giannarelli D, Trozzi R, et al
Less is more? Comparison between genomic profiling and immunohistochemistry-based models in endometrial cancer molecular classification: A multicenter, retrospective, propensity-matched survival analysis.
Gynecol Oncol. 2024;191:150-157.
PubMed Abstract available

OGASAWARA A, Matsushita H, Tan TZ, Shintani D, et al
Immunological impact of intraperitoneal and intravenous chemotherapy in ovarian cancer, translational analyses of the Phase 3 iPocc trial.
Gynecol Oncol. 2024;191:124-131.
PubMed Abstract available

SAAB R, Fellman BM, Legarreta AF, Meyer LA, et al
Comparative analysis of hormonal therapy in low-grade endometrial stromal sarcoma: A retrospective study.
Gynecol Oncol. 2024;191:143-149.
PubMed Abstract available

PINTO P, Moro F, Alcazar JL, Alessi S, et al
Prediction of non-resectability in tubo-ovarian cancer patients using Peritoneal Cancer Index - A prospective multicentric study using imaging (ISAAC study).
Gynecol Oncol. 2024;191:132-142.
PubMed Abstract available

KONG W, Deng B, Shen X, John C, et al
Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer.
Gynecol Oncol. 2024;191:116-123.
PubMed Abstract available

NG ZY, Manchanda R, Lopez A, Obermair A, et al
The prognosis of stage IA cervical cancer: Subgroup analysis of the SCCAN study.
Gynecol Oncol. 2024;191:95-99.
PubMed Abstract available

CARUSO G, Langstraat CL, Kumar A, McGree ME, et al
Textbook oncologic outcome is an easy-to-use composite quality measure that is strongly associated with survival in advanced-stage ovarian cancer.
Gynecol Oncol. 2024;191:86-94.
PubMed Abstract available

RUSHTON T, Krause HB, Samec T, Elliott A, et al
Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma.
Gynecol Oncol. 2024;191:80-85.
PubMed Abstract available

LIAO JB, Jejurikar NS, Hitchcock-Bernhardt KM, Gwin WR, et al
Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer.
Gynecol Oncol. 2024;191:74-79.
PubMed Abstract available

BRITTON MC, Izampuye E, Clark M, Ornstein RA, et al
Diagnostic experiences of Black and White patients with uterine cancer: A qualitative study.
Gynecol Oncol. 2024;191:67-73.
PubMed Abstract available

VAZ J, Piver R, Brzezinska B, Suhner J, et al
Nutrition's checkpoint inhibition: The impact of nutrition on immunotherapy outcomes.
Gynecol Oncol. 2024;189:129-136.
PubMed Abstract available

September 2024

WAN S, Gao Y, Wu S, Wang H, et al
Somatic mutation of targeted sequencing identifies risk stratification in advanced ovarian clear cell carcinoma.
Gynecol Oncol. 2024;191:56-66.
PubMed Abstract available

LINDQUIST S, Kjaer SK, Frederiksen K, Ornskov D, et al
Comparative analysis of HPV testing versus cytology in Danish cervical cancer screening: Insights from a large-scale implementation study.
Gynecol Oncol. 2024;191:45-55.
PubMed Abstract available

PRAISS AM, Dagher C, Zhou Q, Iasonos A, et al
Lymph node metastases in endometrial carcinoma: A modern assessment in the era of sentinel lymph node mapping and molecular subtyping.
Gynecol Oncol. 2024;191:37-44.
PubMed Abstract available

YANG X, Li C, Li Z, Du D, et al
The clinical value of ultrasound-guided sacral anesthesia in Intracavitary and/or interstitial brachytherapy for cervical Cancer.
Gynecol Oncol. 2024;191:31-36.
PubMed Abstract available

LI X, Argenta PA, Brown K, Honeyfield K, et al
Associations of cytomegalovirus infection with cancer-related cognitive impairment and peripheral neuropathy in ovarian cancer survivors.
Gynecol Oncol. 2024;191:25-30.
PubMed Abstract available

JANG EB, Lee AJ, So KA, Lee SJ, et al
Risk factors for the recurrence in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment.
Gynecol Oncol. 2024;191:19-24.
PubMed Abstract available

ANASTASIO MK, Nolin A, Penvose KN, Lambert K, et al
Adjuvant therapy and recurrence risk in non-myoinvasive high-grade (stage IC) endometrial cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2024;191:10-18.
PubMed Abstract available

NIEF CA, Long SE, McCleary TL, Kidd E, et al
Diabetes mellitus complications associated with recurrence of stage I endometrioid endometrial cancer: A single-center retrospective study.
Gynecol Oncol. 2024;190:298-306.
PubMed Abstract available

MOUFARRIJ S, Gazzo A, Rana S, Selenica P, et al
Concurrent POLE hotspot mutations and mismatch repair deficiency/microsatellite instability in endometrial cancer: A challenge in molecular classification.
Gynecol Oncol. 2024;191:1-9.
PubMed Abstract available

FULLERTON R, Martell K, Khanolkar R, Phan T, et al
Impact of immune, inflammatory and nutritional indices on outcome in patients with locally advanced cervical cancer treated with definitive (chemo)radiotherapy.
Gynecol Oncol. 2024;190:291-297.
PubMed Abstract available

BROWN J, Miller A, Holman LL, Backes F, et al
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.
Gynecol Oncol. 2024;190:283-290.
PubMed Abstract available

NAHSHON C, Leitao MM Jr, Segev Y
Response to the letter to the editor: Referring to the manuscript entitled "Surgical nodal assessment for endometrial hyperplasia - A meta-analysis and systematic review".
Gynecol Oncol. 2024;190:262-263.
PubMed

ADJEI NN, Haas A, Zhao H, Primm KM, et al
Real-world trends in the use of maintenance therapy in ovarian cancer across the United States from 2017 to 2021.
Gynecol Oncol. 2024;190:255-261.
PubMed Abstract available

NGUYEN L, Chung TH, Le YL, Reygaerts H, et al
Hispanic individuals' cervical cancer screening disparities amidst the COVID-19 pandemic.
Gynecol Oncol. 2024;190:243-249.
PubMed Abstract available

RIOS-DORIA E, Nobre SP, Sassine D, Glaser G, et al
Impact of adjuvant therapy on oncologic outcomes in uterine-confined clear cell carcinoma of the endometrium.
Gynecol Oncol. 2024;190:236-242.
PubMed Abstract available

MOKSHAGUNDAM S, McGree ME, Tapia AL, Fought AJ, et al
Physical and psychological distress amongst patients undergoing neoadjuvant chemotherapy for advanced ovarian cancer.
Gynecol Oncol. 2024;190:230-235.
PubMed Abstract available

YOUNG AN, Lin LH, Abel MK, Badhey MO, et al
Atypical placental site nodules: Clinicopathologic features, management and patient outcomes in an institutional series.
Gynecol Oncol. 2024;190:215-221.
PubMed Abstract available

POTHURI B, Sawaged Z, Karpel HC, Li X, et al
A phase 2 feasibility study of nab-paclitaxel and carboplatin in epithelial carcinoma of the uterus.
Gynecol Oncol. 2024;190:209-214.
PubMed Abstract available

PIFER PM, Kilar CR, Beriwal S
Is substantial lymphovascular space invasion in FIGO stage I endometrial carcinoma ready for primetime in deciding adjuvant treatment?
Gynecol Oncol. 2024;188:A1-A3.
PubMed

WALL JA, Pozzar RA, Enzinger AC, Tavormina A, et al
Improving the palliative-procedure decision-making process for patients with peritoneal carcinomatosis: A secondary analysis.
Gynecol Oncol. 2024;188:125-130.
PubMed Abstract available

WILKE RN, Iniesta MD, Fellman B, Jazaeri AA, et al
A colostomy for large bowel obstruction at the end of life: What do patients gain from palliative surgery?
Gynecol Oncol. 2024;188:120-124.
PubMed Abstract available

MONK BJ, Tewari KS, Randall LM, Pothuri B, et al
Immunotherapy in locally advanced cervix cancer: A critical appraisal of the FDA indication based on ENGOT-CX11/GOG-3047/KEYNOTE-A18.
Gynecol Oncol. 2024;188:81-82.
PubMed

LAMBERT KA, Albright BB, Anastasio MK, Kaplan SJ, et al
Scalp hypothermia to reduce chemotherapy-induced alopecia: A systematic review and meta-analysis.
Gynecol Oncol. 2024;188:71-80.
PubMed Abstract available

WILHITE AM, Wu S, Xiu J, Gibney GT, et al
A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma.
Gynecol Oncol. 2024;188:13-21.
PubMed Abstract available

POZZAR RA, Enzinger AC, Howard C, Tavormina A, et al
Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomized clinical trial.
Gynecol Oncol. 2024;188:1-7.
PubMed Abstract available

August 2024

LIM H, Kim SI, Kim MK, Yoon SH, et al
Initial sarcopenia and body composition changes as prognostic factors in cervical cancer patients treated with concurrent chemoradiation: An artificial intelligence-based volumetric study.
Gynecol Oncol. 2024;190:200-208.
PubMed Abstract available

MILLER EA, Chowdhary B, Chapman-Davis E
Beyond the decision: Reproductive justice and cervical cancer care in a post-Dobbs era.
Gynecol Oncol. 2024;190:186-188.
PubMed Abstract available

MEERNIK C, Osazuwa-Peters OL, Wilson LE, Joshi A, et al
Frailty in patients with ovarian cancer and the role of healthcare access, race, and ethnicity.
Gynecol Oncol. 2024;190:146-152.
PubMed Abstract available

FRICOVA L, Kommoss S, Scambia G, Ferron G, et al
Reproductive outcomes after fertility-sparing surgery for cervical cancer - results of the multicenter FERTISS study.
Gynecol Oncol. 2024;190:179-185.
PubMed Abstract available

QI C, Lyu M, Yao Z, Zhang F, et al
SVIL promotes ovarian cancer progression and epithelial-mesenchymal transition under hypoxic conditions through the TGF-beta/Smad pathway.
Gynecol Oncol. 2024;190:167-178.
PubMed Abstract available

CHUK E, Conway JL, Hanuschak J, Han K, et al
Patient-reported sexual health outcomes of cervical cancer patients treated with definitive chemoradiation and MRI-guided brachytherapy.
Gynecol Oncol. 2024;190:153-159.
PubMed Abstract available

KATO MK, Fujii E, Yamaguchi M, Higuchi D, et al
Excellent concordance of the molecular classification between preoperative biopsy and final hysterectomy in endometrial carcinoma.
Gynecol Oncol. 2024;190:139-145.
PubMed Abstract available

BARAKZAI SK, Bregar AJ, Del Carmen MG, Eisenhauer EL, et al
The association of maintenance hormone therapy with overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study.
Gynecol Oncol. 2024;190:119-123.
PubMed Abstract available

YUNOKAWA M, Kurihara N, Ishizuka N, Kanao H, et al
Investigating the timing and site of recurrence for ovarian clear cell carcinoma: Analysis of the JGOG/GCIG trial-JGOG 3017-A3.
Gynecol Oncol. 2024;190:113-118.
PubMed Abstract available

SKOF E, Stegel V, Dragos VS, Blatnik A, et al
Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A single center report.
Gynecol Oncol. 2024;190:104-112.
PubMed Abstract available

LEMIEUX M, Telles R, Goodheart M, Dahmoush L, et al
Quality of life and survivorship in patients with low-grade ovarian cancer.
Gynecol Oncol. 2024;190:96-103.
PubMed Abstract available

KOTSOPOULOS J, Lubinski J, Huzarski T, Bychkovsky BL, et al
Incidence of endometrial cancer in BRCA mutation carriers.
Gynecol Oncol. 2024;189:148-155.
PubMed Abstract available

WAGAR MK, Patel UJ, Bharucha K, Heisler CA, et al
Postoperative urinary retention by void trial methodology following radical hysterectomy for cervical cancer.
Gynecol Oncol. 2024;190:90-95.
PubMed Abstract available

GUERRA RA, Kaplan C, Borno H, Boscardin J, et al
The role of race/ethnicity and age in clinical trial knowledge among patients with gynecologic malignancy.
Gynecol Oncol. 2024;190:84-89.
PubMed Abstract available

SUZUKI Y, Chen L, Matsuo K, Ferris JS, et al
Weight-loss therapy in patients with obesity with endometrial intraepithelial neoplasia and uterine cancer.
Gynecol Oncol. 2024;190:78-83.
PubMed Abstract available

GAMBLE CR, Huang Y, Quinn J, Melamed A, et al
Neighborhood economic vulnerability as a predictor for patterns of care and outcomes for patients with uterine cancer.
Gynecol Oncol. 2024;190:70-77.
PubMed Abstract available

ROSS TL, Na R, Au-Yeung G, DeFazio A, et al
Are exercise and sitting time during chemotherapy for ovarian cancer associated with treatment-related side-effects, chemotherapy completion and survival?
Gynecol Oncol. 2024;190:53-61.
PubMed Abstract available

YOKOI A, Machida H, Shimada M, Mastuo K, et al
Efficacy and safety of minimally invasive surgery versus open laparotomy for epithelial ovarian cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2024;190:42-52.
PubMed Abstract available

GU Y, Liu Y, Cheng H, Wang W, et al
Clinicopathological characteristics and oncologic outcomes of patients with gestational trophoblastic neoplasia manifesting as isolated pulmonary lesions.
Gynecol Oncol. 2024;190:28-34.
PubMed Abstract available

CUN HT, Bernard L, Lande KT, Lawson BC, et al
Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma.
Gynecol Oncol. 2024;189:138-145.
PubMed Abstract available

FROEDING LP, Jensen PT
Commentary on "Simple versus radical hysterectomy in women with low-risk cervical cancer" by Plante M. et al. published in The New England Journal of Medicine.
Gynecol Oncol. 2024;189:137.
PubMed

OSTBY SA, Narasimhulu D, Ochs Kinney MA, Cliby W, et al
Defining optimal perioperative analgesia in patients undergoing laparotomy for advanced gynecologic malignancy: A randomized controlled trial.
Gynecol Oncol. 2024;190:11-17.
PubMed Abstract available

RIEDINGER CJ, Sakach J, Maples JM, Fulton J, et al
Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist.
Gynecol Oncol. 2024;190:1-10.
PubMed Abstract available

HOLTZMAN S, Gellman C, Kaplowitz E, Barber E, et al
Yes, it's true: Benign hysterectomy trends for gynecologic oncologists in the United States from 2015 to 2021.
Gynecol Oncol. 2024;189:125-128.
PubMed Abstract available

CHELSEA NN, Posever N, Hsieh TYJ, Patterson S, et al
Implementation of a financial navigation program in gynecologic oncology.
Gynecol Oncol. 2024;189:119-124.
PubMed Abstract available

VAN DER EERDEN B, de Rooij BH, Schouten LJ, Boll D, et al
Quality of life among borderline ovarian tumor survivors: A comparison with survivors of early-stage ovarian cancer and a cancer-free population: A cross-sectional population-based PROFILES study.
Gynecol Oncol. 2024;189:111-118.
PubMed Abstract available

GLASER S, Han E
Optimizing and harmonizing lymph node dissection and radiotherapy in advanced vulvar cancer.
Gynecol Oncol. 2024;187:A1-A2.
PubMed

STROOT IAS, Bart J, Hollema H, Jalving M, et al
Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers.
Gynecol Oncol. 2024;187:198-203.
PubMed Abstract available

WAGAR MK, Naik A, Zhang RC, Godecker A, et al
Incidence of postoperative venous thromboembolism in patients with vulvar carcinoma undergoing vulvectomy with or without lymphadenectomy.
Gynecol Oncol. 2024;187:192-197.
PubMed Abstract available

DEL VALLE D, Ruiz R, Lekuona A, Cobas P, et al
Superparamagnetic iron oxide (SPIO) for sentinel lymph node detection in vulvar cancer.
Gynecol Oncol. 2024;187:145-150.
PubMed Abstract available

VAN DEN BERG CB, Dasgupta S, Ewing-Graham PC, Bart J, et al
Does serous tubal intraepithelial carcinoma (STIC) metastasize? The clonal relationship between STIC and subsequent high-grade serous carcinoma in BRCA1/2 mutation carriers several years after risk-reducing salpingo-oophorectomy.
Gynecol Oncol. 2024;187:113-119.
PubMed Abstract available

ADOLPH L, Mann A, Liu XQ, Roberts L, et al
Follow-up of women with cervical adenocarcinoma in situ treated by conization: A single centre clinical experience.
Gynecol Oncol. 2024;187:74-79.
PubMed Abstract available

VUE NC, Sassani J, Prairie B, Yin Y, et al
Clinical outcomes with utilization of high-potency topical steroids in patients with lichen sclerosus-associated vulvar cancer.
Gynecol Oncol. 2024;187:58-63.
PubMed Abstract available

SWIFT BE, Khoja L, Matthews J, Croke J, et al
Management of inguinal lymph nodes in locally advanced, surgically unresectable, squamous cell carcinoma of the vulva.
Gynecol Oncol. 2024;187:46-50.
PubMed Abstract available

July 2024

DA COSTA AABA, Souza RP, Pandolfi NC, de Souza Castro F, et al
Should we consider progression-free survival benefits enough for drug approvals in locally advanced cervical cancer?
Gynecol Oncol. 2024;189:109-110.
PubMed

JOHANSEN G, Lampic C, Floter Radestad A, Dahm-Kahler P, et al
Health-related quality of life, sexual function, psychological health, reproductive concerns and fertility outcome in young women treated with fertility-sparing surgery for ovarian tumors - A prospective longitudinal multicentre study.
Gynecol Oncol. 2024;189:101-108.
PubMed Abstract available

ZANNONI GF, Santoro A, Arciuolo D, Travaglino A, et al
Endometrial cancer and 2023 FIGO staging system: Not too soon, but maybe too much?
Gynecol Oncol. 2024;189:98-100.
PubMed

GUPTA A, O'Cearbhaill RE, Block MS, Hamilton E, et al
Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial.
Gynecol Oncol. 2024;189:90-97.
PubMed Abstract available

SULLIVAN MW, Kanbergs AN, Growdon WB
Letter to the Editor: Referring to the manuscript entitled "Surgical nodal assessment for endometrial hyperplasia - A meta-analysis and systematic review" recently reported from Nahshon et al. (Gynecol Oncol., 188;140-146;2024).
Gynecol Oncol. 2024;189:88-89.
PubMed

HUEPENBECKER SP, Soliman PT, Meyer LA, Iniesta MD, et al
Perioperative outcomes in gynecologic pelvic exenteration before and after implementation of an enhanced recovery after surgery program.
Gynecol Oncol. 2024;189:80-87.
PubMed Abstract available

FINCH L, Broach V, Feinberg J, Al-Niaimi A, et al
ChatGPT compared to national guidelines for management of ovarian cancer: Did ChatGPT get it right? - A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol. 2024;189:75-79.
PubMed Abstract available

LEE YW, Wang V, Wang MJ, Kim KH, et al
The effects of Asian American Pacific Islander (AAPI) data inequities in gynecologic oncology.
Gynecol Oncol. 2024;189:64-67.
PubMed Abstract available

KAMRAVA MR, Gonzalez-Martin A, Pothuri B, Vergote I, et al
Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012.
Gynecol Oncol. 2024;189:68-74.
PubMed Abstract available

CABRERA S, Bebia V, Lopez-Gil C, Luzarraga-Aznar A, et al
Molecular classification improves preoperative risk assessment of endometrial cancer.
Gynecol Oncol. 2024;189:56-63.
PubMed Abstract available

BERGSTEIN A, Huang Y, Hershman DL, Xu X, et al
Impact of medicaid expansion on cervical cancer screening: A state-specific difference in difference analysis.
Gynecol Oncol. 2024;189:49-55.
PubMed Abstract available

SENGUTTUVAN RN, Lugo-Santiago N, Nakamura B, Song M, et al
Uterine cancer restaging according to the updated 2023 FIGO Guidelines does not uniformly affect prognosis: An institutional retrospective cohort study.
Gynecol Oncol. 2024;189:41-48.
PubMed Abstract available

POLAN RM, Ali-Fehmi R, Grace AK, Mattei LH, et al
Occult residual ovarian tissue at the time of minimally invasive risk reducing surgery in women with BRCA mutations.
Gynecol Oncol. 2024;189:37-40.
PubMed Abstract available

ANDRES S, Finch L, Iasonos A, Zhou Q, et al
Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer.
Gynecol Oncol. 2024;189:30-36.
PubMed Abstract available

MAHONEY DE, Mukherjee R, Thompson J
Elucidating the influences of social determinants of health on perceived overall health among African American/Black and Hispanic ovarian cancer survivors using the NIH All of Us Research Program.
Gynecol Oncol. 2024;189:24-29.
PubMed Abstract available

MCNAMARA B, Greenman M, Bellone S, Santin LA, et al
Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma.
Gynecol Oncol. 2024;189:16-23.
PubMed Abstract available

ARO K, Pasanen A, Butzow R, Loukovaara M, et al
The impact of estrogen receptor and L1 cell adhesion molecule expression on endometrial cancer outcome correlates with clinicopathological risk group and molecular subgroup.
Gynecol Oncol. 2024;189:9-15.
PubMed Abstract available

GRAHAM O, Rodriguez J, Abbott R, Lomonosova E, et al
A toolkit for a modern gynecologic oncology tissue bank.
Gynecol Oncol. 2024;189:1-8.
PubMed Abstract available

EZENDAM NPM, de Rooij BH, Creutzberg CL, Kruitwagen RFPM, et al
Effect of reduced follow-up care on patient satisfaction with care among patients with endometrial cancer: The ENSURE randomized controlled trial.
Gynecol Oncol. 2024;188:169-183.
PubMed Abstract available

KUMAR PP, Smith D, Key J, Dong H, et al
Preclinical 3D model screening reveals digoxin as an effective therapy for a rare and aggressive type of endometrial cancer.
Gynecol Oncol. 2024;188:162-168.
PubMed Abstract available

SHALOWITZ DI, Rajczi A
Refining research on access to gynecologic cancer care: The DIMeS framework.
Gynecol Oncol. 2024;188:158-161.
PubMed Abstract available

CROWLEY F, Broderick S, Francis JH, O'Cearbhaill RE, et al
Ocular side effects of anticancer agents used in the treatment of gynecologic cancers.
Gynecol Oncol. 2024;188:147-157.
PubMed Abstract available

NAHSHON C, Leitao MM Jr, Lavie O, Schmidt M, et al
Surgical nodal assessment for endometrial hyperplasia - A meta-analysis and systematic review.
Gynecol Oncol. 2024;188:140-146.
PubMed Abstract available

STEWART KT, Jafari H, Pattillo J, Santos J, et al
Avoiding the needle: A quality improvement program introducing apixaban for extended thromboprophylaxis after major gynecologic cancer surgery.
Gynecol Oncol. 2024;188:131-139.
PubMed Abstract available

RODRIGUEZ GC, Yozwiak M, Nelson OL, Zhang HH, et al
The karyometric signature is altered in fallopian tubes with serous tubal intraepithelial carcinoma.
Gynecol Oncol. 2024;186:110-116.
PubMed Abstract available

June 2024

FUMAGALLI D, Sonik R, De Vitis LA, Rossi V, et al
Evaluating nutrition in advanced ovarian cancer: which biomarker works best?
Gynecol Oncol. 2024;188:97-102.
PubMed Abstract available

MEADE CE, Sinnott JA, Backes FJ, Cosgrove CM, et al
Associations between race and ethnicity and treatment setting among gynecologic cancer patients.
Gynecol Oncol. 2024;188:111-119.
PubMed Abstract available

MIRZA MR, Tandaric L, Henriksen JR, Maenpaa J, et al
NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer.
Gynecol Oncol. 2024;188:103-110.
PubMed Abstract available

KA K, Cordoba A, Cagetti LV, Schiappa R, et al
Preoperative brachytherapy of early-stage cervical cancer: A multicenter study by the SFRO brachytherapy group.
Gynecol Oncol. 2024;188:90-96.
PubMed Abstract available

KOCIAN R, Kohler C, Bajsova S, Jarkovsky J, et al
Sentinel lymph node pathological ultrastaging: Final outcome of the Sentix prospective international study in patients with early-stage cervical cancer.
Gynecol Oncol. 2024;188:83-89.
PubMed Abstract available

MANNING-GEIST BL, Sullivan MW, Zhou Q, Iasonos A, et al
Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities.
Gynecol Oncol. 2024;188:52-57.
PubMed Abstract available

KOH B, Ryu JY, Noh JJ, Hwang JR, et al
Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant ovarian cancer.
Gynecol Oncol. 2024;188:60-70.
PubMed Abstract available

EKMANN-GADE AW, Hogdall CK, Seibaek L, Noer MC, et al
Corrigendum to "Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study" [Gynecologic Oncology 164/1(2022) 120-128].
Gynecol Oncol. 2024;188:58-59.
PubMed

BHATNAGAR AR, Ghanem AI, Alkamachi B, Allo G, et al
The prognostic impact of substantial lymphovascular space invasion in women with node negative FIGO stage I uterine carcinoma.
Gynecol Oncol. 2024;188:44-51.
PubMed Abstract available

GARZON S, Calio A, Ferrari FA, Iannicello CQ, et al
Uterine perivascular epithelioid cell tumors (PEComa) and the accuracy of proposed classification systems in predicting the malignant versus non-malignant behavior.
Gynecol Oncol. 2024;188:35-43.
PubMed Abstract available

CHEN H, Chen Y, Zheng A, Tan X, et al
Is pharmacologic venous Thromboprophylaxis necessary for patients undergoing minimally invasive surgery for endometrial Cancer? A systematic review and Meta-analysis.
Gynecol Oncol. 2024;188:27-34.
PubMed Abstract available

WALKER CA, Edwards C, McIntire D, Makepeace L, et al
Predicting VTE and utility of thromboprophylaxis in metastatic and recurrent cervical cancer.
Gynecol Oncol. 2024;188:22-26.
PubMed Abstract available

PATEL KB, Escamilla V, Wolfe L, Morris T, et al
Food deserts, endometrial cancer survivors, and healthy food access: Is it equitable in rural America? - A geospatial analysis.
Gynecol Oncol. 2024;188:8-12.
PubMed Abstract available

FLANIGAN MR, Bell SG, Donovan HS, Zhao J, et al
Variables impacting prolonged post-anesthesia care unit length of stay in gynecologic cancer patients in the era of same day minimally invasive hysterectomy.
Gynecol Oncol. 2024;186:211-215.
PubMed Abstract available

BORHO L, Bao R, Elishaev E, Dinkins KD, et al
Association of allostatic load with overall survival in epithelial ovarian cancer.
Gynecol Oncol. 2024;186:204-210.
PubMed Abstract available

CHAN JK, Tewari K, Monk BJ, Herzog TJ, et al
Biomarker guidance in selection among breakthrough treatment options in advanced and recurrent endometrial cancer.
Gynecol Oncol. 2024;187:249-252.
PubMed

MAKKER V, Perez-Fidalgo JA, Valabrega G, Hamilton E, et al
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.
Gynecol Oncol. 2024 Jun 3:S0090-8258(24)00234.
PubMed Abstract available

AISAGBONHI O, Ghlichloo I, Hong DS, Roma A, et al
Comprehensive next-generation sequencing identifies novel putative pathogenic or likely pathogenic germline variants in patients with concurrent tubo-ovarian and endometrial serous and endometrioid carcinomas or precursors.
Gynecol Oncol. 2024;187:241-248.
PubMed Abstract available

VALABREGA G, Pothuri B, Oaknin A, Graybill WS, et al
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Gynecol Oncol. 2024;187:128-138.
PubMed Abstract available

O'CONNOR RM, Huang DS, Rimel BJ, Kim KH, et al
Unmet financial needs among patients crowdfunding to support gynecologic cancer care.
Gynecol Oncol. 2024;186:199-203.
PubMed Abstract available

BERTON D, Pautier P, Lorusso D, Gennigens C, et al
Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I stud
Gynecol Oncol. 2024;186:191-198.
PubMed Abstract available

CHALIF J, Kistenfeger Q, Fulton J, Morton M, et al
Diagnosis and management of gastric-type endocervical adenocarcinoma: A case report and review of the literature.
Gynecol Oncol. 2024;185:165-172.
PubMed Abstract available

SCALISE CB, Kincaid K, Thigpen H, Moore J, et al
A spatial proteomic study of platinum refractory HGSOC implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment.
Gynecol Oncol. 2024;185:83-94.
PubMed Abstract available

FEINBERG J, Da Cruz Paula A, da Silva EM, Pareja F, et al
Adenoid cystic carcinoma of the Bartholin's gland is underpinned by MYB- and MYBL1- rearrangements.
Gynecol Oncol. 2024;185:58-67.
PubMed Abstract available

HOHN AK, Forberger M, Alfaraidi M, Gilks CB, et al
High concordance of molecular subtyping between pre-surgical biopsy and surgical resection specimen (matched-pair analysis) in patients with vulvar squamous cell carcinoma using p16- and p53-immunostaining.
Gynecol Oncol. 2024;185:17-24.
PubMed Abstract available

May 2024

FRANCO S, Godley LA
Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants.
Gynecol Oncol. 2024;187:235-240.
PubMed Abstract available

LOF P, van Soolingen NJ, Piek JMJ, Aarts JWM, et al
Preferences and considerations for interval cytoreductive surgery in advanced ovarian cancer: The patient's perspective.
Gynecol Oncol. 2024;187:227-234.
PubMed Abstract available

PITIYARACHCHI O, Ansell PJ, Coleman RL, Dinh MH, et al
Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
Gynecol Oncol. 2024;187:221-226.
PubMed Abstract available

YUAN G, Zhang K, Zheng H, Wu Y, et al
Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer: A phase 1b dose-escalation trial.
Gynecol Oncol. 2024;187:212-220.
PubMed Abstract available

CARBALLO EV, Kim KH, Penn CA
Trends in estimated PARP inhibitor eligibility and benefit among US epithelial ovarian cancer patients.
Gynecol Oncol. 2024;187:204-211.
PubMed Abstract available

OSAZUWA-PETERS OL, Greiner MA, Kaufman BG, Zambrano Guevara LM, et al
ACO leakage among gynecologic cancer patients: Incidence, predictors, and impact on annual Medicare expenditure.
Gynecol Oncol. 2024;187:184-191.
PubMed Abstract available

PERSSON J, Luhrs O, Geppert B, Ekdahl L, et al
A prospective study evaluating an optimized sentinel node algorithm in early stage cervical cancer: The PROSACC-study.
Gynecol Oncol. 2024;187:178-183.
PubMed Abstract available

MARCHETTI C, Ataseven B, Perrone AM, Cassani C, et al
Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status.
Gynecol Oncol. 2024;187:170-177.
PubMed Abstract available

LARAJA A, Connor Y, Poulson MR
The effect of urban racial residential segregation on ovarian cancer diagnosis, treatment, and survival.
Gynecol Oncol. 2024;187:163-169.
PubMed Abstract available

FERRIS JS, Prest MT, Hur C, Chen L, et al
Trends in uterine cancer incidence in the United States: The contribution of age, period and cohort effects.
Gynecol Oncol. 2024;187:151-162.
PubMed Abstract available

ZENATRI M, Perennec T, Michon C, Gernier F, et al
Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study.
Gynecol Oncol. 2024;187:139-144.
PubMed Abstract available

HUNSBERGER KS, Treiman S, Monk BJ, Tewari KS, et al
A systematic review of stage IVA cervical cancer treatment: Challenges in the management of an understudied group.
Gynecol Oncol. 2024;187:120-127.
PubMed Abstract available

LIU JF, Xiong N, Wenham RM, Wahner-Hendrickson A, et al
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.
Gynecol Oncol. 2024;187:105-112.
PubMed Abstract available

ROSATI A, De Rose AM, Gallotta V, Giannarelli D, et al
Feasibility and operative outcomes of surgery in the liver area in advanced ovarian cancer.
Gynecol Oncol. 2024;187:98-104.
PubMed Abstract available

PIEDIMONTE S, Murray C, Atenafu EG, Rouzbahman M, et al
Correlating the KELIM (CA125 elimination rate constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma.
Gynecol Oncol. 2024;187:92-97.
PubMed Abstract available

KIM JH, Han KH, Park EY, Kim ET, et al
Efficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in advanced or recurrent endometrial cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2024;187:85-91.
PubMed Abstract available

FILIPPOVA OT, Boecking K, Broach V, Gardner GJ, et al
Trends in specific procedures performed at the time of cytoreduction for ovarian cancer: Is interval debulking surgery truly less radical? A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol. 2024;187:80-84.
PubMed Abstract available

LIANG S, Ge H, Zhou S, Tang J, et al
Prognostic factors of 87 ovarian yolk sac tumor (OYST) patients and molecular characteristics of persistent and recurrent OYST.
Gynecol Oncol. 2024;187:64-73.
PubMed Abstract available

CHIBA Y, Kojima Y, Yazaki S, Yoshida H, et al
Trop-2 expression and the tumor immune microenvironment in cervical cancer.
Gynecol Oncol. 2024;187:51-57.
PubMed Abstract available

GONZALEZ-MARTIN A, Chung HC, Saada-Bouzid E, Yanez E, et al
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
Gynecol Oncol. 2024;186:182-190.
PubMed Abstract available

MATSUO K, Chen L, Klar M, Lee MW, et al
Prognostic performance of the 2023 FIGO staging schema for endometrial cancer.
Gynecol Oncol. 2024;187:37-45.
PubMed Abstract available

MITRIC C, Sayyid RK, Fleshner NE, Look Hong NJ, et al
Hysterectomy versus chemotherapy for low-risk non-metastatic gestational trophoblastic neoplasia (GTN): A cost-effectiveness analysis.
Gynecol Oncol. 2024;187:30-36.
PubMed Abstract available

PAPPAS TC, Roy Choudhury M, Chacko BK, Twiggs LB, et al
Neural network-derived multivariate index assay demonstrates effective clinical performance in longitudinal monitoring of ovarian cancer risk.
Gynecol Oncol. 2024;187:21-29.
PubMed Abstract available

DEMIRKIRAN C, Greenman M, Bellone S, McNamara B, et al
Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas.
Gynecol Oncol. 2024;187:12-20.
PubMed Abstract available

RING KL, Duska LR
How far is too far? Cancer prevention and clinical trial enrollment in geographically underserved patient populations.
Gynecol Oncol. 2024;184:8-15.
PubMed Abstract available

MACCHIA G, Cilla S, Pezzulla D, Campitelli M, et al
Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer.
Gynecol Oncol. 2024;184:16-23.
PubMed Abstract available

April 2024

HOLTZMAN S, McCarthy L, Estevez SL, Lee JA, et al
Walking the tightrope: Fertility preservation among hereditary breast and ovarian Cancer syndrome Previvors.
Gynecol Oncol. 2024;186:176-181.
PubMed Abstract available

JIANG Z, Zhu M, Zhang L, Cui H, et al
Antitumor immunity and prognosis value elicited by FAT3 and LRP1B co-mutation in endometrial cancer.
Gynecol Oncol. 2024;187:1-11.
PubMed Abstract available

HOFFMAN M, Dunsmore V, Cliby W, Chi D, et al
Surgical training of gynecologic oncology fellows: Long-term trends and implications for future education.
Gynecol Oncol. 2024;184:254-258.
PubMed Abstract available

SMITH AJB, O'Brien C, Haggerty A, Ko EM, et al
"Having cancer is very expensive": A qualitative study of patients with ovarian cancer and PARP inhibitor treatment.
Gynecol Oncol. 2024;186:170-175.
PubMed Abstract available

CHALIF J, Chambers LM, Yao M, Kuznicki M, et al
Extended-duration antibiotics are not associated with a reduction in surgical site infection in patients with ovarian cancer undergoing cytoreductive surgery with large bowel resection.
Gynecol Oncol. 2024;186:161-169.
PubMed Abstract available

PENG H, Jiang J, Li L, Hao Z, et al
Mismatch repair deficiency and abnormal p53 expression has significant predictive value for progesterone resistance and endometrial tumorigenesis in patients with endometrial atypical hyperplasia receiving fertility-preserving treatment.
Gynecol Oncol. 2024;186:154-160.
PubMed Abstract available

ALGERA MD, van Driel WJ, Slangen BFM, Wouters MWJM, et al
Effect of surgical volume on short-term outcomes of cytoreductive surgery for advanced-stage ovarian cancer: A population-based study from the Dutch Gynecological Oncology Audit.
Gynecol Oncol. 2024;186:144-153.
PubMed Abstract available

PATEL JM, Hermann CE, Growdon WB, Aviki E, et al
ChatGPT accurately performs genetic counseling for gynecologic cancers.
Gynecol Oncol. 2024;183:115-119.
PubMed Abstract available

WANG CC, Grubbs A, Foley OW, Bharadwa S, et al
The activity advantage: Objective measurement of preoperative activity is associated with postoperative recovery and outcomes in patients undergoing surgery with gynecologic oncologists.
Gynecol Oncol. 2024;186:137-143.
PubMed Abstract available

ZHAO Z, Wang J, Kong W, Fang Z, et al
Intermittent energy restriction inhibits tumor growth and enhances paclitaxel response in a transgenic mouse model of endometrial cancer.
Gynecol Oncol. 2024;186:126-136.
PubMed Abstract available

NELSON AT, Harris AK, Watson D, Kamihara J, et al
Outcomes in ovarian Sertoli-Leydig cell tumor: A report from the International Pleuropulmonary Blastoma/DICER1 and Ovarian and Testicular Stromal Tumor Registries.
Gynecol Oncol. 2024;186:117-125.
PubMed Abstract available

EHMANN S, Lam C, Zhou Q, Iasonos A, et al
Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer.
Gynecol Oncol. 2024;186:104-109.
PubMed Abstract available

ESPINOSA I, D'Angelo E, Prat J
Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging.
Gynecol Oncol. 2024;186:94-103.
PubMed Abstract available

MATSUO K, Huang Y, Matsuzaki S, Vallejo A, et al
Cesarean hysterectomy for placenta accreta spectrum: Surgeon specialty-specific assessment.
Gynecol Oncol. 2024;186:85-93.
PubMed Abstract available

GITTO SB, Ihewulezi CJN, Powell DJ Jr
Adoptive T cell therapy for ovarian cancer.
Gynecol Oncol. 2024;186:77-84.
PubMed Abstract available

DAHM-KAHLER P, Radestad AF, Holmberg E, Borgfeldt C, et al
Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? - A population-based nationwide SweGCG study.
Gynecol Oncol. 2024;186:69-76.
PubMed Abstract available

GIEN LT, Enserro DM, Block MS, Waggoner S, et al
Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.
Gynecol Oncol. 2024;186:61-68.
PubMed Abstract available

SAYLOR KW, Fernandes EQ, Adams M, Paraghamian S, et al
Predictors of germline genetic testing referral and completion in ovarian cancer patients at a Comprehensive Cancer Center.
Gynecol Oncol. 2024;186:53-60.
PubMed Abstract available

KOPELMAN ZA, Tian C, Tumas J, Phippen NT, et al
Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials.
Gynecol Oncol. 2024;183:103-114.
PubMed Abstract available

HOLLIS RL, Elliott R, Dawson JC, Ilenkovan N, et al
High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.
Gynecol Oncol. 2024;186:42-52.
PubMed Abstract available

VESZTERGOM D, Teglas G, Bahrehmand K, Torok A, et al
Reducing radicality in fertility-sparing surgery is associated with improved in vitro fertilization outcome in early-stage cervical cancer: A national retrospective study.
Gynecol Oncol. 2024;186:35-41.
PubMed Abstract available

Introduction to SGO VSI.
Gynecol Oncol. 2024;183:A7.
PubMed

RIEDINGER CJ, Barrington DA, Nagel CI, Khadraoui WK, et al
Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer" [Gynecologic Oncology 183 (2024) 78-84].
Gynecol Oncol. 2024;183:R1.
PubMed

March 2024

MONTEMORANO L, Shultz ZB, Farooque A, Hyun M, et al
TP53 mutations and the association with platinum resistance in high grade serous ovarian carcinoma.
Gynecol Oncol. 2024;186:26-34.
PubMed Abstract available

SHEN X, Wang J, Deng B, Chen S, et al
High-dose ascorbate exerts anti-tumor activities and improves inhibitory effect of carboplatin through the pro-oxidant function pathway in uterine serous carcinoma cell lines.
Gynecol Oncol. 2024;183:93-102.
PubMed Abstract available

SALINARO JR, Rossi EC, Penvose KN, Zhang Y, et al
Delayed publication of clinical trials in gynecologic oncology.
Gynecol Oncol. 2024;183:74-77.
PubMed Abstract available

HUANG Y, Rauh-Hain JA, McCoy TH, Hou JY, et al
Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning.
Gynecol Oncol. 2024;186:9-16.
PubMed Abstract available

DESRAVINES N, Hazimeh D, Desjardins MR, Wethington SL, et al
Healthcare utilization in women diagnosed with endometrial cancer: A survey-based study.
Gynecol Oncol. 2024;186:1-8.
PubMed Abstract available

WILLIAMS-BROWN MY, Summey RM, Newtson A, Burke W, et al
System-level recommendations for improved wellness for gynecologic oncologists: A Society of Gynecologic Oncology Review.
Gynecol Oncol. 2024;183:85-92.
PubMed Abstract available

RIEDINGER CJ, Barrington DA, Nagel CI, Khadraoui WK, et al
Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer.
Gynecol Oncol. 2024;183:78-84.
PubMed Abstract available

KIM NK, Choi CH, Seong SJ, Lee JM, et al
Treatment outcomes according to various progestin treatment strategies in patients with atypical hyperplasia/endometrial intraepithelial neoplasia - Multicenter retrospective study (KGOG2033).
Gynecol Oncol. 2024;183:68-73.
PubMed Abstract available

PASSARELLI A, Carbone V, Pignata S, Mazzeo R, et al
Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.
Gynecol Oncol. 2024;183:61-67.
PubMed Abstract available

LIANG MI, Dholakia JD, Lee GM, Wang L, et al
Dedicated financial hardship screening adds value to routine distress screening among gynecologic cancer patients.
Gynecol Oncol. 2024;183:53-60.
PubMed Abstract available

AHSAN MD, Webster EM, Wolfe IA, McGonigle R, et al
Personalized survivorship care: Routine breast cancer risk assessment in the gynecologic oncology clinic.
Gynecol Oncol. 2024;183:47-52.
PubMed Abstract available

HARTMAN YAW, Kenkhuis MF, Stelten S, Brouwer CG, et al
Demographic, clinical, and sociocognitive determinants related to physical activity and dietary intake in patients with ovarian cancer: A cross-sectional study.
Gynecol Oncol. 2024;183:39-46.
PubMed Abstract available

LEVINE BJ
Letter re: Ban et al., A personalized probabilistic approach to ovarian cancer diagnostics.
Gynecol Oncol. 2024 Mar 15:S0090-8258(24)00155.
PubMed

ROSS DH, Gomez K, Harmon G, Mysz ML, et al
Evaluating outcomes and toxicities for a newly implemented MRI-based brachytherapy program for cervical cancer.
Gynecol Oncol. 2024;183:33-38.
PubMed Abstract available

CACCIOTTOLA L, Camboni A, Gatti E, Marbaix E, et al
Fertility potential and safety assessment of residual ovarian cortex in young women diagnosed with epithelial borderline and early-stage malignant ovarian tumors.
Gynecol Oncol. 2024;183:15-24.
PubMed Abstract available

BYRNE M, Sia TY, Fong C, Khurram A, et al
Mainstreaming in parallel with ovarian cancer tumor testing to improve genetic testing uptake.
Gynecol Oncol. 2024 Mar 14:S0090-8258(24)00144.
PubMed Abstract available

GASS P, Thiel FC, Haberle L, Ackermann S, et al
Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer.
Gynecol Oncol. 2024;183:25-32.
PubMed Abstract available

BJERRE TRENT PK, Nordskar NJ, Wangen KR, Engeskaug MI, et al
Corrigendum to "Self-reported lower extremity lymphedema and quality of life after surgical staging of endometrial carcinoma: A population based cross-sectional study" [Gynecologic Oncology 175 (2023) 72-80].
Gynecol Oncol. 2024;183:7-8.
PubMed

GLASER GE, Maddy B, Kumar A, Ishitani K, et al
Impact of pharmacogenomic profiles on post-surgical pain following laparotomy for gynecologic pathology.
Gynecol Oncol. 2024;183:9-14.
PubMed Abstract available

PANDYA D, Tomita S, Rhenals MP, Swierczek S, et al
Mutations in cancer-relevant genes are ubiquitous in histologically normal endometrial tissue.
Gynecol Oncol. 2024;185:194-201.
PubMed Abstract available

GAFFNEY D, Matias-Guiu X, Mutch D, Scambia G, et al
2023 FIGO staging system for endometrial cancer: The evolution of the revolution.
Gynecol Oncol. 2024;184:245-253.
PubMed Abstract available

RICHARDSON DL, Moore KN, Vergote I, Gilbert L, et al
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
Gynecol Oncol. 2024;185:186-193.
PubMed Abstract available

NOGUEIRA-RODRIGUES A, Giannecchini GV, Secord AA
Real world challenges and disparities in the systemic treatment of ovarian cancer.
Gynecol Oncol. 2024;185:180-185.
PubMed Abstract available

OLAWAIYE AB
2023 FIGO staging for endometrial cancer, a look at both sides of the coin.
Gynecol Oncol. 2024;184:243-244.
PubMed

EJAREDAR M, Ruzycki SM, Glazer TS, Trudeau P, et al
Implementation of a surgical site infection prevention bundle in gynecologic oncology patients: An enhanced recovery after surgery initiative.
Gynecol Oncol. 2024;185:173-179.
PubMed Abstract available

GLASER GE, Dowdy SC
Sentinel lymph node biopsy in high-risk endometrial cancer: The denouement.
Gynecol Oncol. 2024;182:A1-A2.
PubMed

CHEN W, Xie J, Gao C, Zhang C, et al
Hypertension associated with niraparib in cancer patients: A pharmacovigilance analysis based on the FAERS database and meta-analysis of randomized controlled trials.
Gynecol Oncol. 2024;182:108-114.
PubMed Abstract available

February 2024

CAO B, Li Y, Liu Y, Chen X, et al
A multi-center study to predict the risk of intraoperative hypothermia in gynecological surgery patients using preoperative variables.
Gynecol Oncol. 2024;185:156-164.
PubMed Abstract available

CHEN Y, Yang J, Wan Y, Li Q, et al
DEAR model in overweight endometrial cancer patients undergoing fertility-sparing treatment: A randomized controlled trial.
Gynecol Oncol. 2024;185:148-155.
PubMed Abstract available

COSTALES AB, Crane EK, Chambers L, Yao M, et al
Laparoscopic predictability of minimally invasive interval debulking in advanced ovarian cancer: The MIID-SOC trial.
Gynecol Oncol. 2024;185:143-147.
PubMed Abstract available

SALMAN L, Covens A, Vicus D, Podolsky S, et al
The role of surgeon specialty in management and survival of malignant ovarian germ cell tumors: A population-based study.
Gynecol Oncol. 2024;185:138-142.
PubMed Abstract available

RONCOLATO F, King MT, O'Connell RL, Lee YC, et al
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
Gynecol Oncol. 2024;185:128-137.
PubMed Abstract available

AGUSTI N, Kanbergs A, Nitecki R
Potential of molecular classification to guide fertility-sparing management among young patients with endometrial cancer.
Gynecol Oncol. 2024;185:121-127.
PubMed Abstract available

MCNAMARA B, Demirkiran C, Hartwich TMP, Bellone S, et al
Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.
Gynecol Oncol. 2024 Feb 9:S0090-8258(24)00043.
PubMed Abstract available

APPLEBAUM AJ
The importance of family-focused care in the setting of advanced gynecological cancers.
Gynecol Oncol. 2024;181:A1-A2.
PubMed

PELTECU G
Eugen Bogdan Aburel, a pioneer of fertility sparing surgery.
Gynecol Oncol. 2024;181:40-45.
PubMed Abstract available

VASTA FM, Cormio G, Cassani C, Bergamini A, et al
Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs.
Gynecol Oncol. 2024;181:28-32.
PubMed Abstract available

TAYLOR DD, Gercel-Taylor C, Parker LP
Retraction notice to "Patient-derived tumor reactive antibodies as diagnostic markers for ovarian cancer" [Gynecologic Oncology 115 (2009) 112-120].
Gynecol Oncol. 2024;181:186.
PubMed

January 2024

FADER AN, Ko EM, Pollock BD, Blank SV, et al
An SGO commentary: U.S. News and World Report gynecologic oncology procedural ratings-Do they reflect high-quality care?
Gynecol Oncol. 2024 Jan 25:S0090-8258(24)00002.
PubMed Abstract available

October 2023

KIM JH, Kim SI, Park EY, Ha HI, et al
Impact of postoperative residual disease on survival in epithelial ovarian cancer with consideration of recent frontline treatment advances: A systematic review and meta-analysis.
Gynecol Oncol. 2023;179:24-32.
PubMed Abstract available

HALL TR, MacDonald JE, Bylinowski KM, Alvarez EA, et al
Management of chemotherapy hypersensitivity reactions and desensitization: An SGO clinical practice statement.
Gynecol Oncol. 2023;177:180-185.
PubMed Abstract available

HUI C, Mendoza MG, von Eyben R, Dorigo O, et al
Does lymph node assessment change the prognostic significance of substantial LVSI and p53 status in endometrial endometrioid carcinoma?
Gynecol Oncol. 2023;177:150-156.
PubMed Abstract available

TOBONI MD, Wu S, Farrell A, Xiu J, et al
Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 "Lynch-like" mismatch repair gene mutation.
Gynecol Oncol. 2023;177:132-141.
PubMed Abstract available

LIM H, Ju Y, Kim SI, Park JH, et al
Clinical implications of histologic subtypes on survival outcomes in primary mucinous ovarian carcinoma.
Gynecol Oncol. 2023;177:117-124.
PubMed Abstract available

SPAGNOL G, Marchetti M, De Tommasi O, Vitagliano A, et al
Simple rules, O-RADS, ADNEX and SRR model: Single oncologic center validation of diagnostic predictive models alone and combined (two-step strategy) to estimate the risk of malignancy in adnexal masses and ovarian tumors.
Gynecol Oncol. 2023;177:109-116.
PubMed Abstract available

SAAB RH, Salvo G, Gonzales NR, Munsell MF, et al
Social media use is associated with higher levels of anxiety and depression in patients with neuroendocrine carcinoma of the cervix: A NeCTuR study.
Gynecol Oncol. 2023;177:95-102.
PubMed Abstract available

NASIOUDIS D, Fernandez ML, Wong N, Powell DJ Jr, et al
The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches.
Gynecol Oncol. 2023;177:86-94.
PubMed Abstract available

MORTON M, McLaughlin EM, Calo CA, Lightfoot M, et al
Prevalence of type 2 diabetes diagnoses in the perioperative and survivorship periods following surgical management of endometrial cancer: An opportunity for screening and intervention?
Gynecol Oncol. 2023;177:46-52.
PubMed Abstract available

NASIOUDIS D, Latif NA, Ko EM, Cory L, et al
Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma.
Gynecol Oncol. 2023;177:14-19.
PubMed Abstract available

LEE MW, Vallejo A, Mandelbaum RS, Yessaian AA, et al
Temporal trends of failure-to-rescue following perioperative complications in vulvar cancer surgery in the United States.
Gynecol Oncol. 2023;177:1-8.
PubMed Abstract available

September 2023

MARSH LA, Kim TH, Zhang M, Kubalanza K, et al
Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival.
Gynecol Oncol. 2023;177:173-179.
PubMed Abstract available

AGUSTI N, Viveros-Carreno D, Mora-Soto N, Ramirez PT, et al
Diagnostic accuracy of sentinel lymph node frozen section analysis in patients with early-stage cervical cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2023;177:157-164.
PubMed Abstract available

LEE HC, Jeong JW, Lee JH, Kim SH, et al
High-dose (60 Gy) intensity-modulated radiotherapy with concurrent weekly cisplatin followed by intracavitary radiation in locally advanced cervical cancer: A phase II prospective clinical trial.
Gynecol Oncol. 2023;177:142-149.
PubMed Abstract available

August 2023

NARAYAN P, Ahsan MD, Webster EM, Perez L, et al
Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2023;177:72-85.
PubMed Abstract available

AO W, Kim HI, Tommarello D, Conrads KA, et al
Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment.
Gynecol Oncol. 2023;177:60-71.
PubMed Abstract available

MARJON N, Guerra R, Freeman A, Mak J, et al
Same day service: A genetic testing station model to improve germline genetic testing in patients with ovarian cancer.
Gynecol Oncol. 2023;177:53-59.
PubMed Abstract available

KIM JH, Park KN, Park EY, Jang MJ, et al
Impact of warm saline irrigation, hyperthermic intraperitoneal chemotherapy on postoperative pain in primary ovarian cancer from the KOV-HIPEC-01 randomized trial.
Gynecol Oncol. 2023;177:32-37.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum